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Dengue virus is a flavivirus that infects millions of people every year, causing high fever and 
rash and resulting in death in some cases. There are four serotypes (DENV-1, DENV-2, DENV-
3, and DENV-4) of dengue virus that are transmitted by the Aedes aegypti mosquito, endemic to 
tropical and subtropical regions of the world. Currently no vaccine for dengue fever is available. 
The rising number of confirmed cases and the increased habitat of Aedes aegypti increase the 
urgent need for a vaccine. Together with the Centers for Disease Control, Inviragen Inc. has 
developed a tetravalent live attenuated chimeric vaccine (DENVax) that is currently in phase II 
clinical trials. 
DENVax is based on an attenuated DENV-2 backbone. DENV-2 strain 16681 was passaged 53 
times in primary dog kidney (PDK) cells. This strain is the current DENVax-2 strain used in 
Inviragen’s vaccine. There are nine attenuating mutations, three of which are silent. Attenuating 
phenotypes of DENVax-2 include temperature sensitivity, decreased plaque size, and decreased 
replication efficiency in mosquito cells. To generate DENVax-1, DENVax-3, and DENVax-4, 
prM and E genes from wild type DENV-1, DENV-3, and DENV-4 strains were cloned into the 
infectious cDNA clone of the attenuated DENVax-2 backbone, resulting in chimeras. Tetravalent 
DENVax has shown significant immunogenic responses in AG129 mice and non-human 
primates, and is currently in phase II clinical testing. 
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Data from preclinical tests showed that DENVax-4 is less immunogenic in AG129 mice and 
non-human primates compared to the other DENVax strains. Two projects in this thesis were 
completed to reengineer the current DENVax-4 strain to increase immunogenicity. The first 
project uses blind serial passaging of DENVax-4 first generation and reengineered DENVax-4b 
second generation as a method to select for strains better fit to grow in vivo. These passaged 
strains were tested for increased growth kinetics and immunogenicity in both AG129 mice and 
non-human primates. The second project uses sequencing data from the serial passaging to 
identify several adaptive mutations in each DENVax-4 construct. These mutations were cloned 
into DENVax-4 sequence to potentially optimize the strains for Vero cell growth. Three new 
DENVax-4 constructs were introduced, each containing a different mutation. In addition three 
new DENVax-4 constructs with wild type reversions of non-critical attenuating mutations were 
generated. Growth kinetics for all six new DENVax-4 clones were characterized, and testing was 
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DENGUE VIRUS AND DENVAX LITERATURE REVIEW 
 
 
1.1 DENGUE PREVALENCE 
!
Four dengue virus serotypes exist (DENV-1, DENV-2, DENV-3, and DENV-4) which are 
capable of causing human disease. Averages of 100 million cases of dengue fever are reported 
each year, with up to 1 million cases of dengue hemorrhagic fever/ dengue shock syndrome 
(DHF/DSS) (6). DHF/DSS causes approximately 22,000 deaths per year, the majority of these 
deaths occurring in children. Dengue virus is transmitted by the mosquito Aedes aegypti that 
lives in the tropical and subtropical regions of the world. Due to the wide-ranging habitat of this 
mosquito, approximately 2.5 billion people are at risk of developing dengue fever, with more 
cases being reported annually (6). The number of reported cases since 2000 is twice that from 
1990-1999 (Figure 1.1). This is a result of a larger mosquito habitat (attributed to global 
warming), increased travel, and uncontrolled urbanization in endemic areas, increasing 
population density. The rise in the number of annual cases of dengue fever greatly exemplifies 
the need for a vaccine, but currently there are no licensed vaccines available. An ideal dengue 
vaccine would protect against all four serotypes (to prevent secondary exposure) with only one 
or two doses, be easy to administer and inexpensive to manufacture, and produce no or minimal 





Figure 1.1 Global distribution of dengue virus serotypes in 1970 (top) and 2004 (bottom) 
Guzman M et al. (2010) Dengue: a continuing global threat. Nature Reviews: S7-S16.
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1.2 DENGUE VIRUS STRUCTURE 
!
Dengue virus is a flavivirus that is a member of the family Flaviridae. The enveloped virus has a 
positive sense single stranded RNA genome (1) containing a 5’ type I cap, but lacks a 3’ poly 
(A) tail. The mRNA has high purine content, and translates into a polyprotein that is cleaved into 
3 structural proteins and 7 nonstructural proteins. The DENV structural proteins consist of the 
capsid, prM, and envelope proteins. The capsid protein is small and is the main component of the 
nucleocapsid. The protein has a central hydrophobic region with hydrophilic domains at the N 
and C termini (1). Each capsid monomer contains 4 alpha helices, and the mature capsid protein 
assembles into a dimer (41). The membrane protein is formed by cleavage of the precursor 
membrane protein (prM) at position 91 at the C terminus. The prM protein forms a heterodimer 
with the E protein that is believed to be important for stability during maturation. Upon cleavage 
of the pr segment the mature virion is released from the infected cell (45). DENV envelope 
proteins are found on the surface of the viral membrane and have roles in virion assembly, 
receptor binding, and membrane fusion (Figure 1.2) (4). The E protein has three different 
domains that play an important role in virus infection, and is the main immunogenic protein of 
dengue virus (5). Domain I is a beta barrel. Domain II contains the conserved fusion loop that 
inserts into the endosome membrane during infection. Domain III is responsible for cell receptor 
binding, and is the primary target for neutralizing antibodies that are very virus specific (40). The 
Domain III structure also contains the hairpin anchor that attaches the E protein to the viral 
membrane. This structure consists of two alpha helices separated by a region with a sequence 




    
 
Figure 1.2 Model of structure of DENV-2. Structure is based on cryo-EM density and crystal 
structure of E-protein. 
 





The 7 nonstructural proteins are NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5. All the 
nonstructural proteins play an important role in virus life cycle and infection, mostly because 
they regulate these processes. NS1 is a beta barrel with amphipathic properties (3). It is 
synthesized as a monomer during viral replication, but dimerizes in the endoplasmic reticulum 
and is secreted from infected cells as a hexamer. Although NS1 is essential for virus replication, 
it is not known what its exact role is during pathogenesis of DENV (42). The NS2 sub-region of 
the polyprotein contains two small hydrophobic proteins, NS2A and NS2B. NS2A is a protein 
that spans the membrane of the ER lumen, with the N terminus inside the ER near the C terminus 
of the NS1 protein. It is believed to contain a peptide sequence that signals for cleavage of NS1 
(50). NS2B is a cofactor for the protease domain of NS3 (49). NS3 is highly conserved and has a 
protease domain and helicase domain (1). The protease domain is at the N terminus and cleaves 
the NS3/4A, NS4 internal site, and NS4B/5. The helicase domain is at the C terminus and 
unwinds double stranded RNA and DNA, which is essential for viral replication (43). The NS4 
sub-region of the polyprotein contains two small hydrophobic proteins NS4A and NS4B, similar 
to the NS2 proteins described previously. NS4A colocalizes with RNA during viral replication, 
and may have an anchoring role (52). The exact role of NS4B is unknown, but studies have 
shown it associates with NS5 and is involved with the RNA polymerase (51). NS5 has a methyl-
tranferase in the N-terminal domain and a RNA-dependent RNA polymerase in the C-terminal 







1.3 DENGUE VIRUS LIFE CYCLE 
!
Dengue viruses enter host cells through receptor mediated endocytosis, which is initiated by 
attachment of the E protein to a variety of receptors on the host cell membrane (Figure 1.4).  
Proposed receptors include lectins and mannose receptors found on macrophages and dendritic 
cells (53). Once inside an endosome, the low pH triggers irreversible rearrangement of the E 
protein into homotrimers, after the pre-fusion dimers dissociate to form monomers (3) (Figure 
1.5). This exposes fusion loops located in Domain II that initiate fusion of the virus membrane 
with the endosome membrane through the C-terminal E protein anchor, allowing viral RNA to 
enter the cytoplasm and begin replication. Once inside the cell the capsid dissociates and the 
mRNA is released into the cytoplasm. Host-cell machinery is used to translate the polyprotein, 
which is cleaved by viral proteases upon translation. Viral mRNA for new virus particles is 
synthesized by the NS5 RNA polymerase. A copy of the mRNA interacts with capsid proteins 
via the basic domain to form a nucleocapsid precursor (1). Envelope and prM, proteins anchor 
themselves to the ER membrane through their C termini, with their ectodomains in the ER 
lumen. New virus particles are budded into the ER lumen once the virus proteins are assembled. 
These immature virus particles then follow a secretory pathway to the plasma membrane, 
stabilized by the pr segment of the prM protein bound to the E protein. This inhibits the E 
proteins from fusing with the membrane of the golgi apparatus. Just before release into the 




Figure 1.3 Overview of dengue virus replication and life cycle. The dengue virion binds to cell 
surface receptors and enters the cell via endocytosis. Low pH in the endosome causes the E 
protein to mediate fusion between membranes and release the viral RNA genome into the 
cytoplasm. After RNA replication and viral protein synthesis immature virions are assembled 
and budded into the golgi apparatus. Prior to release from the cell the precursor membrane 
protein segment is cleaved from the membrane protein, producing a mature virion.  
 
Tomlinson SM et al. (2009) New approaches to structure-based discovery of dengue protease 




Figure 1.4 Dimeric structure of the E protein on the virus envelope membrane. A) Prior to 
pH change in endosome the E protein lies on the virus envelope membrane in a dimeric 
structure.  B) The reduction of pH in the endosome causes the E protein to “fan out” from the 
envelope membrane and form a trimeric structure. 
 
Schmidt AG et al. (2010) Peptide Inhibitors of Dengue-Virus Entry Target a Late-Stage Fusion 
Intermediate. PLoS Pathogens 6(4): e1000851
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1.4 MOSQUITO REPLICATION CYCLE 
!
Aedes aegypti mosquitoes are endemic to tropical and subtropical regions, commonly found in 
South and Central America, Africa, India and Southeast Asia (32). Their habitat has recently 
extended to more temperate zones because of the adaption to reproduce during the warmer 
seasons. Aedes aegypti is believed to have used slave ships in the 15th century to migrate from 
West Africa to the Americas. The mosquito breeds in stagnant pools, such as in vases or tires 
filled with rainwater, in urban areas where the large dense populations provide adequate food 
sources (32). Dengue viruses exist in an urban cycle between humans and Aedes aegypti 
mosquitoes.  Dengue viruses replicate in the midgut of the mosquito upon ingestion, which 
occurs when the mosquito feeds on blood from an infected (and viremic) human (31). Humans 
that can infect mosquitoes have peak viremia titers in their systems 4-7 days after being bitten by 
an infected mosquito (37). Ideal replication temperature in mosquitoes is 28°C (31). The virus 
replicates for 10 days in the mosquito midgut and reaches a peak titer of approximately 9 x 103 
plaque-forming units per mL (PFU/mL) before disseminating to the salivary glands, where it is 
further amplified and injected into a host with saliva when the mosquito bites (6). Current studies 
suggest that Aedes aegypti mosquitoes use RNA interference (RNAi) to control virus infection. 
The RNAi pathway is characterized by recognizing double-stranded RNA (dsRNA) in the 
cytoplasm of cells infected with RNA viruses. The dsRNA is targeted for degradation by RNAi 
sensor proteins, which cleave the dsRNA into several short interfering RNAs (siRNAs). One 
strand of these siRNAs is used by the RNA-induced silencing complex (RISC) to target 
complementary ssRNA for degradation. This process does not completely inhibit dengue virus 
replication in Aedes aegypti, but studies show that knocking out genes involved in the RNAi 
10 
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pathway in Aedes aegypti decreases the incubation time required for sufficient replication of 
dengue virus for transmission (31). 
 
 
1.5 VIRAL REPLICATION AND TREATMENT IN HUMANS 
!
Once a DEN-infected mosquito bites a human, the virus is transmitted with saliva into the skin 
and bloodstream (6). Virus in the skin infects dendritic cells, which then migrate to the lymph 
nodes to activate T cells and initiate an immune response. Virus in the blood stream migrates 
throughout the body and can infect macrophages, monocytes, endothelial cells in the liver, 
lymphoid tissue in the spleen, and vascular endothelium of the lungs (36). Clinical symptoms of 
illness usually develop 4-7 days after infection through a mosquito bite, when peak viremia titer 
is reached. There are three phases to dengue fever; the febrile phase, the critical phase, and the 
recovery phase (37). During the 5-7 day period of the febrile phase symptoms include high fever, 
arthralgia and myalgia, nausea and possibly vomiting. The critical phase occurs 3-7 days after 
development of symptoms. During this phase symptoms of DHF or DSS could occur. The 
primary symptom of DHF is increased capillary permeability due to low platelet count, causing 
fluid leakage. Loss of vascular fluids when these symptoms appear results in development of 
DSS, caused by fluids leaking into the interstitial space. However, most patients do not develop 
these symptoms and instead proceed directly into the recovery phase. During the recovery phase 
the fever should subside and platelet count will rise. Some individuals develop a rash during this 
phase. The best form of treatment for dengue fever is monitoring of symptoms and 
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administration of fluid IV (37). DENV is not transmissible between humans and cannot be 
spread by person to person contact. The only preventive method against dengue transmission is 
mosquito control using mosquito nets, insecticide, and larval habitat reduction. However, with 
increased mosquito habitats available the mosquito is better able to transmit the virus within 
human populations and because of the rising mosquito density more humans are at a much 
higher risk of becoming infected (6). 
 
 
1.6 VIRUS NEUTRALIZATION AND ANTIBODY DEPENDENT ENHANCEMENT 
!
 
Infection by one serotype of DENV confers lifelong immunity to that serotype.  Infection 
produces neutralizing antibodies in the host, which are effective at neutralizing the virus if 
reinfection occurs.  Neutralization of DENV is dependent on both antibody affinity and epitope 
accessibility. Serotype specific neutralizing epitopes are found primarily in Domain III of the E 
protein. Domains I and II contain weak, non-neutralizing, and/or cross reactive epitopes. Most 
antibodies produced during infection with a DENV target epitopes in Domain II of the E protein 
(34). Studies have shown that antibodies which target the fusion loop in Domain II have a higher 
affinity to immature virions. The large amount of weak antibodies produced also competes with 
the small amount of strong neutralizing antibodies produced for binding sites. Often the 
neutralizing antibodies are inhibited by steric interference, contributing to the severity of 
infection (34). Antibodies can either bind to proteins on the surface of the virion to prevent 
attachment to cellular receptors or bind to the fusion loop on the envelope protein to prevent 
12 
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fusion of the virion to the endosome membrane. However, surface antibodies that fail to 
neutralize virus particles also increase uptake of the virus by monocytes via the Fc gamma 
receptor (35), possibly increasing the severity of infection. 
 
Neutralizing antibodies are serotype specific, and the host is still susceptible to infection by the 
other three DENV serotypes after infection with a single serotype. Virus neutralization is one of 
the most important factors in preventing development of DHF/DSS (37). DHF/DSS more 
frequently occurs after a secondary infection by a heterologous DENV serotype, and is believed 
to be the result of antibody-dependent enhancement (ADE). ADE occurs when pre-existing 
antibodies from a previous dengue infection bind to another dengue serotype but fail to 
neutralize the virion (7, 8). This complex then binds to monocytic cells bearing Fc! receptors. 
Once the complex is taken up by the cells the virus, since it has not been neutralized, can infect 
the monocytes and cause severe illness. The most frequent cases of DHF/DSS occur in children, 
since by the time most reach adulthood they have already been exposed to all four serotypes and 
therefore have complete immunity (6).  Recent studies have shown that DHF/ DSS are more 
likely to occur when primary infection is from DENV-1 or DENV-3, and secondary infection is 
from DENV-2. Studies have also shown that humans can be infected with more than one dengue 
serotype and not have symptoms of DHF/DSS (26). However, secondary infection with another 







1.7 DENGUE VACCINE CANDIDATES 
!
1.7.1 TYPES OF VACCINES 
!
There are several different types of vaccines currently used. Live attenuated vaccines contain a 
pathogen that has been mutated to decrease its pathogenicity so that it can still replicate in the 
host, but doesn’t cause clinical symptoms (15). Chimeric vaccines use viruses that are built from 
the genomes of more than one virus. These viruses use an attenuated virus backbone with genes 
coding for immunogenic proteins inserted. This is a common method to generate vaccines 
against viruses from the same family. Killed or inactivated vaccines used pathogens that have 
been killed or inactivated so they don’t replicate, but induce an immune response by introducing 
the host to immunogenic proteins still intact on the pathogen surface. Protein or DNA subunit 
vaccines consist of only select purified proteins from the pathogen as opposed to the entire 
molecule. Introducing these proteins into the host induces an immune response to provide future 
protection against pathogens that express those proteins. 
 
 
1.7.2 WALTER REED ARMY INSTITUTE OF RESEARCH VACCINE 
!
The Walter Reed Army Institute of Research (WRAIR) developed a live attenuated tetravalent 
dengue vaccine in partnership with GlaxoSmithKline Biologicals (15). Vaccine viruses were 
obtained by serial passaging of wild dengue viruses obtained from patients with clinical disease 
(56). Viruses were passaged in primary dog kidney cells and fetal rhesus lung cells. Two studies, 
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single-dose and two-dose, were completed with a total of 49 volunteers using monovalent 
vaccines. Tetravalent vaccine was tested in 10 volunteers using 2 or 3 doses. Yellow fever 
control vaccine was tested in 4 volunteers.  Overall seroconversion rates after a single dose in 
volunteers immunized with monovalent vaccine were 100% for DENV-1, 92% for DENV-2, 
46% for DENV-3, and 58% for DENV-4 (56). Overall seroconversion rates in volunteers 
immunized with tetravalent vaccine were 100% for DENV-1, 80% for DENV-2, 80% for 
DENV-3, and 40% for DENV-4. Development of rash was seen in 13 volunteers (22%) and 
development of fever >100.4 F was seen in 11 volunteers (19%). Most of the clinical symptoms 
were seen in volunteers immunized with monovalent DENV-1, suggesting under attenuation of 
the strain. The vaccine has been reformulated to increase attenuation of DENV-1 and decrease 
attenuation of DENV-4, and is currently in phase II clinical trials.  
 
 
1.7.3 SANOFI PASTEUR VACCINE 
!
Sanofi Pasteur has developed a tetravalent vaccine that uses the yellow fever vaccine attenuated 
backbone with prM and E genes for each dengue serotype inserted. Currently the vaccine is in 
Phase III clinical trials. Results published from the phase II clinical trials show that vaccine 
efficacy after one dose was 61.2% for DENV-1, 0% for DENV-2, 81.9% for DENV-3, and 
90.0% for DENV-4 (48). The sample size was 4002; 2269 children received the dengue vaccine 
and 1333 received the control. There were 76 confirmed cases of dengue fever after at least one 
injection. Of the confirmed cases, 52 were DENV-2 infection. The total vaccine efficacy after 
two injections was 35.3%. These data indicate that further investigation in the DENV-2 vaccine 
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construct is needed, even though the immunogenicity of the DENV-2 vaccine strain was 
satisfactory. Sanofi Pasteur is currently investigating whether balanced immunogenicity against 
all four dengue serotypes is the most effective way to provide immunity (12). 
 
 
1.7.4 LID/NIAID VACCINE 
!
The Laboratory of Infectious Diseases (LID) at the National Institute of Allergy and Infectious 
Diseases (NIAID) are using an infectious cDNA clone for an attenuated DENV-4 backbone (15). 
The clone has 30 base pairs deleted in the 3’ untranslated region. This deletion restricts 
dissemination to the head in mosquitoes, inhibiting virus transmission. Clinical testing in 20 
volunteers showed no serious adverse reactions and a 100% seroconversion rate (57). The PrM 
and E genes were replaced in this backbone with genes from the other 4 serotypes, resulting in 
three chimeric vaccine strains which are formulated into a tetravalent vaccine. These constructs 
are currently in preclinical testing. 
 
 
1.7.5 ARBOVAX INC. VACCINE 
!
Arbovax Inc. has partnered with North Carolina State University to develop a dengue vaccine 
with attenuation properties in the E protein transmembrane domain (47). The DENV-2 mRNA 
sequence has large truncations in this domain, which has been shown to decrease replication in 
vertebrate cells but not in invertebrate cells (i.e. mosquitoes). The large deletions make reversion 
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to the wild type sequence upon multiple passages very difficult. Three vaccine candidates 
containing different mutant strains of DENV-2 were tested in African green monkeys and 
generated sufficient neutralizing antibodies against DENV-2 upon challenge. Constructs for the 
other three dengue serotypes using this method of attenuation have not been synthesized. 
 
 
1.8 INVIRAGEN’S DENGUE VACCINE 
!
!
1.8.1 DEVELOPMENT OF DENVAX-2 BACKBONE 
!
Scientists at Mahidol University in Bangkok, Thailand developed the DENVax-2 backbone that 
is currently the backbone of Inviragen’s dengue vaccine. The candidate DENV-2 vaccine was 
constructed by isolating DENV-2 from a patient in Thailand with DHF/DSS (strain 16681). The 
wild type DENV-2 was then passaged in primary dog kidney (PDK) cells 53 times. Cells were 
grown at 32ºC and passages were done without any deliberate selection. The serial passages 
caused mutation of the viral genome, which conferred significant attenuation in the RNA 
genome (22). These attenuation markers were later characterized and mapped by Claire Huang 
and Richard Kinney at the CDC and included temperature sensitivity, small plaque size and 
moderate growth in monocytes (20).  In 1984 ten adult participants were inoculated with the 
DENV-2 vaccine candidate. None of the participants showed any symptoms of infection, and 
adverse reactions were observed at the injection site. All participants developed a neutralizing 




1.8.2 IDENTIFICATION AND SIGNIFICANCE OF ATTENUATING MUTATIONS 
!
Scientists at the Centers for Disease Control and Prevention (CDC) in Fort Collins, Co identified 
9 attenuation markers/mutations in DENV-2 PDK-53 which differentiate this vaccine strain from 
the WT 16681 virus (20). Three of these attenuation markers are silent mutations. The remaining 
six are at 5’ NC-57 C-to T, PrM-29 Asp-to-Val, Gly-to-Asp at NS1-53, NS2A-181 Leu-to-Phe, 
NS3-250 Glu-to-Val, and NS4A-75 Gly-to-Ala. Generation of DENV-2 PDK-53 created two 
different variants. PDK-53V contains all nine attenuation markers listed above, and PDK-53E 
contains eight of nine, having wild type NS3-250 Glu. Inviragen’s DENV vaccine is based on 
the PDK-53V backbone.  
 
Experiments have shown that the PDK-53 strains have smaller plaque size, greater temperature 
sensitivity, lower titer, and reduced growth rate (20) as compared to wild type DENV-2. These 
are all classical signs of attenuation that are important in a vaccine, since the goal of attenuation 
is to produce a virus that cannot replicate enough to cause clinical symptoms. The PDK-53 strain 
also shows decreased replication in mosquitoes (20), which will lessen the probability of the 
vaccine virus from being transmitted. Studies have indicated that 5’ NC, NS1, and NS3 
mutations contribute to the smaller plaque size and affect virus replication. The NS1 and NS3 
mutations also cause temperature sensitivity of the PDK-53 virus. Clinical trials show high 






1.8.3 CONSTRUCTION OF CDNA CLONES 
!
Scientists at the CDC amplified virus stocks of both DENV-2 16681 and DENV-2 PDK-53. The 
RNA genome was extracted and reverse transcription PCR (RT-PCR) was used to amplify 
cDNA. The DENV-2 PDK-53V virus is the vaccine strain for dengue 2 (DENVax2). DENVax1, 
3, and 4 were created by inserting the genes for the prM/E proteins of each serotype into 
DENVax2 (19, 21). Infectious cDNA clones were made for each construct using the pBR322 
plasmid and PDK-53V. The prM/E genes from the parent DENV strains were cloned into the 
plasmid (22) (Figure 1.6). DENVax-1 contains prM and E genes from DENV-1 16007 (Thailand 
1964). DENVax-3 contains prM and E genes from DENV-3 16562 (Philippines 1964). 
DENVax-4 contains prM and E genes from DENV-4 1036 (Indonesia 1976). Once amplified the 
DNA was transcribed into viral RNA and electroporated into cells for virus amplification and 
sequencing. A few attenuating mutations were noted for each virus. DENVax-1, DENVax-2, 
DENVax-3, and DENVax-4 were then formulated into a tetravalent vaccine that theoretically 
protects against all four serotypes (16). 
 
 
1.9 DENGUE 4 PHYLOGENY 
!
The DENV-4 serotype has undergone much evolution from the original strain introduced into the 
Western hemisphere in 1981. DENV- 4 was spread first from Indonesia into the Pacific Islands 




Figure 1.5 DENVax chimera structure for each serotype. The prM and E genes from each 
serotype were cloned into the DENVax-2 PDK-53 backbone to create vaccine strains for each 
dengue serotype. DENVax-1 (green), DENVax-2 (pink), DENVax-3 (blue), and DENVax-4 
(yellow) all showed significant attenuation. Minus signs indicate reduced growth rate in 




strains, with strains from east and southeast Asia in one genotype and strains from the Americas 
in separate genotypes (25). The genotypes were developed based on differences in sequence in 
the E protein. Studies have shown that while a vaccine strain derived from a genotype two virus 
provides antibodies against genotypes one and two, a vaccine strain derived from genotype one 
only provides antibodies against genotype one viruses (25). Recent studies have developed a new 
phylogenic tree for DENV-4 viruses with three genotypes instead of two as well as a grouping of 
sylvatic strains believed to infect populations of wild monkeys. The three genotypes are based on 
entire sequence homology, with more recently evolved strains in genotype three (24) DENVax-4 
prM and E genes come from DENV-4 1036, which belongs to genotype two.  
 
 
1.10 STATEMENT OF PROJECTS 
!
While Inviragen’s DENV-4 vaccine shows promise to protect humans from DENV-4 infection, 
improvement is needed to increase immunogenicity, or the level of neutralizing antibody titers. 
Previous studies have shown that DENVax-4 produces lower neutralizing antibody titers in 
AG129 mice when compared to the other DENVax strains. This thesis encompasses two projects 
that focus on further development and testing of DENVax-4. The first project attempts to 
increase the growth efficiency of the current DENVax-4 strain by blind serial passaging in 
mammalian cell culture, which is a common method to select for strains more fit to grow in vivo. 
Ten blind serial passages were completed to potentially increase Vero cell adaptation of the 
DENVax-4 first generation and DENVax-4b second generation vaccines. DENVax-4b contains 
modifications at the Capsid/prM junction and was previously tested for increased growth 
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kinetics. Blind serial passaging of DENVax-4 and DENVax-4b produced two new candidate 
DENVax-4 strains, DENVax-4-P10 and DENVax-4b-P10. An analysis of growth kinetics in 
Vero cell culture was done on these strains to compare to DENVax-4. Virus was grown in cells 
for 12 days and samples taken on each day were plaque titrated to measure growth rate and peak 
titer. Genome sequencing was completed and significant mutations between the P1 and P10 
strains were identified in the DENVax-4 and DENVax-4b constructs. Immunogenicity in AG129 
mice and non-human primates was also tested and compared to DENVax-4 first generation. 
 
The second thesis project involves incorporating genome changes into the DENVax-4 construct 
to potentially increase immunogenicity. Previous studies showed that DENVax-4 strains 
containing wild type DENV-2 backbone instead of the PDK-53 backbone produced higher 
neutralizing antibody titers. Reversion of the attenuating mutations in the PDK-53 backbone to 
wild type sequence were introduced into the DENVax-4 genome and tested for increased growth 
rate in cell culture. In addition, constructs containing mutations noted after the blind serial 
passaging of DENVax-4 and DENVax-4b were cloned and tested. Growth rate was measured in 
mammalian cells for 12 days. Samples taken on each day were titrated by immunofocus assay. 
Growth rate in mosquito cells was also measured to test for attenuation compared to wild type 
DENV-4. After growth kinetics were completed immunogenicity of selected constructs was 
tested in AG129 mice. Mice were given a single dose of a designated DENVax-4 construct on 
day 0, and then challenged on day 56 with DENV-2. Serology and viremia were measured at 




2 CHAPTER 2 
ADAPTATION OF DENVAX-4 BY SERIAL PASSAGES IN VERO CELLS 
 
 
2.1 BACKGROUND AND RATIONALE 
!
A live attenuated vaccine has a significant advantage over a vaccine containing inactivated 
pathogens or immunogenic proteins. Live attenuated vaccines tend to elicit stronger and longer 
lasting immune responses in the host because there is active replication of a pathogen, but the 
replication efficiency is decreased. This results in no or minimal clinical symptoms produced 
upon vaccination. The significant advantage of a chimeric vaccine is its ability to elicit a strong 
immunogenic response in the host against multiple strains or serotypes of a virus while using a 
single backbone as the vaccine platform, eliminating the need to attenuate multiple virus strains 
Dengue virus has 4 different serotypes. Development of a vaccine against all 4 serotypes is made 
easier by developing a single attenuated backbone and inserting genes to ensure that 
immunogenic proteins from all 4 dengue serotypes are expressed. During the preclinical research 
and development of DENVax-4 three different chimeras were produced.  All three chimeras 
contain the prM and E genes from DENV-4 1036, but contain different backbones. D2/4-P 
contains the DENV-2 strain 16681 backbone, D2/4-E contains the PDK-53-E backbone (which 
has all but one of the attenuating mutations found in the DENVax-2 backbone), and D2/4-V 
contains the PDK-53-V backbone, which contains all the attenuating mutations found in 
DENVax-2 and is the construct used to create the current DENVax-4 strain. These three 
chimeras were tested for immunogenicity in AG129 mice and compared with the wild-type 
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DENV-4 1036. The D2/4-P chimera showed similar immunogenicity to DENV-4 1036, but 
antibody titers in mice injected with D2/4-E or D2/4-V were significantly reduced (21). These 
results indicate that modification of the DENVax-4 clone may be needed to improve 
immunogenicity in AG129 mice. The hypothesis tested by a previous graduate student at 
Inviragen was to modify the current DENVax-4 strain to contain a capsid/prM junction to be 
more genetically similar to DENV-4 instead of DENV-2 to potentially improve replication 
efficiency of the virus. The current strain of DENVax-4 has a capsid/prM sequence that is 
identical to DENV-2 instead of DENV-4, creating a RNA secondary structure different than that 
of DENV-4 (55). The difference in RNA secondary structure affects RNA stability and function.  
Inserting these modifications in the capsid/prM sequence to make the sequence similar to 
DENV-4 instead of DENV-2 may improve the RNA stability and translation by inducing a RNA 
secondary structure more like that of DENV-4, and possibly increase DENVax-4 replication in 
vitro and in vivo.  
 
A previous graduate student at Inviragen produced three new DENVax-4 constructs (DENVax-
4b, DENVax-4c, and DENVax-4d) by designing synthetic fragments containing the 
modifications for each construct and cloning them into the DENVax-4 plasmid (55). DENVax-
4b contains 7 total amino acid changes, DENVax-4c contains 9 total amino acid changes, and 





Figure 2.1 Modifications done to the Capsid/prM junction in each of the DENVax-4b, 4c 
and 4d constructs. Changes were made in the amino acid sequence to synonymize with the 
DENV-4 sequence instead of DENV-2 sequence. In the capsid gene, DENVax-4b has six amino 
acid changes, DENVax-4c has eight, and DENVax-4d has eight changes and one deletion. All 
three constructs have two amino acid changes in the prM gene. 
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transcribed and electroporated into Vero cells for virus rescue. DENVax-4d did not grow to 
sufficient titers after electroporation, and was not used in future experiments. DENVax-4b and 
DENVax-4c were tested for growth efficiency in Vero and C6/36 cells in a growth kinetics 
experiment, with DENVax-4-P2, DENVax-4-P8 and DENVax-2-P2 used as controls. DENVax-
4-P2 and DENVax-2-P2 are virus samples that have not been genotypically selected by viral 
plaque purification, a process in which individual viral plaques are picked from a DENVax-
infected Vero cell monolayer and then over-laid with agarose gel containing neutral red to 
visualize single plaques. DENVax-4-P8 had been selected by plaque purification to obtain a 
virus stock with a clonal DENVax-4 genotype. This procedure is done to generate a master seed 
virus with no reversion of attenuating mutations. DENVax-4c did not reach an adequate peak 
titer after growth in Vero cells, and had a slower initial growth rate than either DENVax-4 or 
DENVax-4b (Figure 2.2). There was no significant difference between the peak titers of 
DENVax-4 and DENVax-4b in the Vero growth curve, and both had similar initial growth rates 
(Figure 2.2). In the growth analysis in C6/36 mosquito cells, DENVax-4b and DENVax-4c both 
reached peak titers that were significantly less than wild type DENV-4, confirming their 
attenuation (Figure 2.3).  
 
Based on the data from this study, further reengineering of the DENVax-4 construct is needed to 
potentially increase immunogenicity. Passaging in cell culture is a classic method of selecting for 
virus strains with adaptive mutations for increased replication rates in vivo, and was one of the 
principal methods in developing the DENVax-2 attenuated backbone. The Vero growth curve 






Figure 2.2 Growth curve of the modified DENVax-4 constructs in Vero cells. New DENVax-4 second generation constructs 
(D2/4-B and D2/4-C) were compared in duplicate with first generation DENVax-4-P2, DENVax-2-P2, and plaque purified DENVax-
4-P8. The day each sample was taken is on the x-axis and the titer of the sample is on the y-axis.  
 




Figure 2.3 Growth curve results of DENVax-4 modified constructs in C6/36 mosquito cells. New DENVax-4 second generation 
constructs (D2/4-B and D2/4-C) were tested for decreased growth rate in mosquito cells compared to wild type DENV-4 1036. The 
day each sample was taken is given on the x-axis and the titer of each sample is on the y-axis. 
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being plaque-purified, DENVax-4-P8 had been passaged six additional times in Vero cells 
compared to DENVax-4-P2, suggesting that adaptation of the vaccine strain in Vero cells could 
increase growth efficiency. The hypothesis is that if DENVax-4 and DENVax-4b are both 
adapted to Vero cells by subsequent passaging in vitro, mutations will be introduced into the 
DENV genome that select for higher replication efficiency. In this study, DENVax-4 and 
DENVax-4b were blindly passaged 10 consecutive times in Vero cells with the goal of adapting 
the viruses to grow more efficiently in Vero cells.  This adaptation allowed us to identify 
mutations which directed the design of two new vaccine candidate strains, DENVax-4-passage 
1(P1) and DENVax-4b-P10.   Growth kinetics of the resulting strains were analyzed in a Vero 
growth curve experiment. The passage 1 and passage 10 strains were sequenced to identify 
mutations that occurred as a result of serial passaging.   
 
 
2.2 MATERIALS AND METHODS 
!
2.2.1 CELL CULTURE 
!
Vero cells are mammalian cells derived from African green monkey kidney. The Vero cell line 
used in the in vitro experiments was obtained from Inviragen’s vaccine certified cell bank, 
produced at Waisman Manufacturing, Madison, WI. Vero cells were grown at 37ºC with 5% 
CO2 in Dulbecco’s modification of Eagle’s Medium (DMEM, Mediatech Inc., Manassas VA) 
supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan UT), 2% L-glutamine (200 
mM) (Hyclone), and 1% penicillin-streptomycin (Pen-Strep, Hyclone). To passage the cells 
Tryple Express solution (1X laboratory derived trypsin) (Life Technologies, Grand Island NY) 
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was used to remove the cells from the flask surface. Cells were diluted 1:24 for passage once a 
week, and passaged 20 times before new cells were thawed.  
!
!
2.2.2 VIRAL INFECTION OF VERO CELL MONOLAYERS 
!
Vero cells (5x105 cells/mL) were seeded on T-75 cm2 flasks approximately 48 hours before 
infection. DMEM supplemented with 10% FBS, 2% L-glutamine, and 1% Pen-Strep was used as 
cell growth medium. Upon confluence 1 flask was treated with 4 mL of Tryple Express solution 
(laboratory synthesized trypsin) to detach cells from the surface. Cells from the flask were 
counted to establish a multiplicity of infection (MOI) at 0.001. Two of the remaining flasks were 
infected with 1 mL of either DENVax-4-P2 (first generation DENVax-4) or DENVax-4b-P3 
diluted in BA-1 diluent (bovine serum albumin, 1X M199, 0.05M tris-HCl, 1X L-glutamine, 
7.5% sodium bicarbonate, 1X pen-strep, 1X fungizone). Viruses were adsorbed onto Vero cells 
for 90 minutes with rocking every 10 minutes to prevent drying of cell monolayers. After 
adsorption 20 mL DMEM supplemented with 5% FBS were added to each flask without removal 
of inoculum. Flasks were incubated for 7 days at 37°C. 
 
 
2.2.3  VIRAL HARVESTS AND SUBSEQUENT INFECTIONS: BLIND PASSAGE 
!
On Day 7 of virus growth, the CPE was observed on each flask and virus-containing supernatant 
was harvested and stabilized in 20% FBS for storage at -80ºC. Previously seeded confluent T-75 
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cm2 Vero flasks were infected with 1 mL of the viral supernatant from the preceding flask. Virus 
was adsorbed for 90 minutes with rocking every 10 minutes. After viral adsorption, 20 mL 
DMEM 5% FBS was added to each flask. New non-infected control flasks were plated every 7 
days. This process was repeated every 7 days for 10 subsequent weeks, yielding 10 passages per 
virus denoted either DENVax-4-P1 through P10 or DENVax-4b-P1 through P10.    
 
 
2.2.4 PLAQUE TITRATION OF VIRUSES 
!
Harvests of DENVax-4-P2 and DENVax-4b-P3 from weeks 1, 5 and 10 were plaque titrated to 
measure infectious virus titer. Virus samples were serially diluted 1x10-1 to 1x10-6 in BA-l 
diluent. Samples were plaque titrated in triplicate, and 100 !L of each dilution was adsorbed to a 
pre-seeded 6-well plate of Vero cells for 90 minutes with rocking every 8 minutes. After 
adsorption wells were overlaid with 4 mL of a 1:1 mixture of balanced salt solution (BSS) 
(NaCl, KCl, NaH2PO4-H2O, glucose, CaCl2-2H2O, MgSO4-7H2O) and1.6% agarose solution and 
incubated for 4 days at 37ºC. Inoculum was not removed prior to overlay. On day 4 wells were 
over-laid with 2 mL BSS/1.6% agarose solution supplemented with neutral red (MP 
Biomedicals, Santa Ana, CA) and incubated overnight at 37ºC. Neutral red solution is adsorbed 
only by living cells, so virus plaques with dead cells will be visible against the red cell 





2.2.5 GROWTH CURVE ANALYSIS 
!
The growth kinetics of the adapted strains were analyzed by performing a growth curve on Vero 
cells. Vero flasks were seeded as previously described. On day 0 a confluent flask of Vero cells 
was counted to calculate the virus PFU needed to infect the flasks at an MOI of 0.001. Flasks 
were infected with 1 mL of DENVax-4, DENVax-4b-P1, DENVax-4b-P10, or DENVax-2. 
Viruses were adsorbed to the monolayers for 90 minutes with rocking every 8 minutes. After 
adsorption, 10 mL DMEM without FBS supplemented with 1% F-127 (Inviragen patented 
product that enhances viral growth) (DMEM-F127) was added to each flask and the samples 
were incubated at 37ºC. Samples were collected from the supernatant from each flask on day 2 
and days 4-12. Viruses were harvested by collecting the entire amount of the supernatant in the 
flask, and the growth medium was replaced with fresh DMEM-F127 medium on day 4 and days 
6-12. Flasks were washed 3 times with phosphate buffered saline (PBS) during medium changes. 
Samples were stabilized in 1x FTA (15% trehalose, 1% F-127, 0.1% human serum albumin, 





To identify mutations accumulated during serial passaging, viral RNA from DENVax-4-P1 and 
P10 and DENVax-4b-P1 and P10 was sequenced at the CDC. Viral RNA was isolated from virus 
stocks using a QIAmp viral RNA kit. Reverse transcription PCR (RT-PCR) was used to 
transcribe the RNA into DNA, using primers previously designed by Claire Huang and Richard 
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Kinney at the CDC. The primers are based on the genome sequences of DENV-2 16681 and 
DENV-4 1036. Approximately 7-9 DNA fragments per construct were amplified through RT-
PCR. The DNA fragments were then sequenced by Beckman Coulter Genomics (Danver, MA) 
using an automated sequencing reaction, and aligned for comparison. 
 
 
2.2.7 IMMUNIZATION IN AG129 MICE 
!
To test for immunogenicity DENVax-4b-P1 and DENVax-4b-P10 were inoculated in AG129 
mice. There were 4 groups of mice (DENVax-4, DENVax-4b-P1, DENVax-4b-P10, and FTA) 
with 10 animals per group. On day 0 mice were subcutaneously injected with either 105 PFU/mL 
virus dose or FTA. Mice were boosted on day 42 and bled on days 21, 42, and 56 for serology. 
Morbidity and mortality were monitored for the duration of the study. All animal testing was 
done at Inviragen in Madison, WI. Mouse sera samples were sent to Inviragen in Fort Collins for 
analysis. Neutralizing antibody titers were determined by plaque reduction neutralization test. 
 
 
2.2.8 PLAQUE REDUCTION NEUTRALIZATION TEST 
!
To test for neutralizing antibodies against DENV-4 in sera samples, a plaque reduction 
neutralization assay was used. Vero 6-well plates were seeded 2 days before inoculation to 
ensure monolayer confluence. Serum samples were diluted serially two-fold in BA-1 diluent in a 
96-well plate and incubated with DENV-4 for approximately 20 hours at 4ºC. After incubation 
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Vero wells were inoculated with prepared virus/serum dilutions. Samples were adsorbed for 90 
minutes with rocking every 8 minutes to prevent drying of the monolayers. After adsorption 
wells were over-laid with 1:1 solution of BSS and 1.6% agarose, and incubated at 37ºC for 4 
days. On day 4 cells were over-laid with a 1:1 ratio of BSS/ 1.6% agarose solution supplemented 
with neutral red. Plaques visible on wells were counted on days 5, 6, and 7.  
 
 
2.2.9 NON-HUMAN PRIMATE STUDY 
!
Testing in non-human primates (NHP) was performed by our colleagues at the Inviragen 
facilities in Madison, WI. Cynomolgus macaques were placed in 5 different study groups and 
vaccinated with varying doses of tetravalent DENVax. There were 5 different vaccine 
formulations and 1 formulation per group was tested. Formulation 1 contained a high dose (105) 
of DENVax with DENVax-4 first generation. Primates in Group 1 were inoculated with 2 doses 
on day 0 and given no boost. Formulation 2 contained a high dose of DENVax with DENVax-
4b-P10. Primates in Group 2 were inoculated with 2 doses on day 0 and given no boost. 
Formulation 3 contained increased DENVax-4 in the high dose DENVax (106). Primates in 
Group 3 were inoculated with 2 doses on day 0 and given no boost. Formulation 4 contained 
increased DENVax-4 in the high dose DENVax. Primates in Group 4 were inoculated with 1 
dose on day 0 and boosted with 1 dose on day 60. Formulation 5 contained increased DENVax-4 
and decreased DENVax-2 in the high dose DENVax. Primates in Group 5 were inoculated with 
one dose on day 0 and boosted with 1 dose on day 60. The vaccine was administered sub-
cutaneous by using a needle and syringe. Serum samples were taken on days 0, 28, 58, 73, 90, 
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2.3.1 CYTOPATHIC EFFECTS DURING SERIAL PASSAGES 
!
Cytopathic effects (CPE) describe the change in appearance of cells after infection with a virus. 
The infected cell is stressed producing large amounts of virus and has abnormal organelle 
function and decreased replication. As a result the cell will detach from the flask and most 
eventually die by apoptosis. Viruses cause different CPE in various cell lines. Attenuated dengue 
viruses do not generate much CPE in Vero cells when grown in vitro, but the presence of CPE 
can indicate successful virus infection and high titer growth. Classical CPE appearance of 
dengue infected Vero cells are cell rounding and floating. Infected cells will “shrivel” into a 
smaller round cell. These cells are termed “rounders”. Rounders will eventually detach from the 
flask and float in the medium. These cells are termed “floaters”. CPE is analyzed by estimating 
the percentage of the cells that have become rounders and floaters. CPE was observed weekly on 
each flask before harvest of media and graded using the qualitative Vero cell culture CPE scale 
(Table 2.1). While both flasks showed high numbers of floaters, DENVax-4-P2 showed more 
floaters than DENVax-4b-P3 (Table 2.2). Both flasks showed similar high numbers of rounders. 
There was no cell detachment on any of the flasks. Control flasks showed high numbers of 





Table 2.1 Cell CPE scale used to grade expression of CPE on Vero cell monolayers. 
“Rounders” (R) refers to cells that have balled up but not completely detached from the flask. 
“Floaters” (F) refers to the rounded cells that have detached from the flask. 
 
 
Scale Cytopathic Effects (CPE) 
- No CPE, no or very few rounders/floaters 
F+ No CPE, some floaters/rounders 
F1 Floaters= low density 
F2 Floaters= intermediate density 
F3 Floaters= high density 
F4 Floaters= very high density 
R1 Rounders= low density 
R2 Rounders= intermediate density 
R3 Rounders= high density 
1 Cells detach, clear 1-5% of plastic 
2 Cells detach, clear 6-15% of plastic 
3 Cells detach, clear 16-30% of plastic 
4 Cells detach, clear 31-50% of plastic 
5 Cells detach, clear >50% of plastic 





Table 2.2 CPE of DENVax-4 and DENVax-4b in Vero cells. CPE was measured weekly 
during blind serial passaging. Cells were graded according to the Vero CPE scale (Table 2.1) by 
estimating the number of rounders and floaters in the cell medium and the percent of cells 







1 F1, R1 F1, R1 
2 F2, R3 F2, R3 
3 F3, R3 F3, R3 
4 F3, R3 F4, R3 
5 F2, R3 F3, R3 
6 F2, R3 F2, R3 
7 F3, R3 F2, R3 
8 F3, R3 F2, R3 
9 F3, R3 F4, R3 






2.3.2 GROWTH KINETICS 
!
DENVax-2 was included as a control and displayed the highest initial titer at day 2, followed by 
DENVax-4b-P10, DENVax-4, and DENVax-4b-P1 (Figure 2.4). At the end of the growth period 
(day 12) DENVax-2 had the highest peak titer, followed by DENVax-4b-P10, DENVax-4b-P1, 
and DENVax-4. However, the calculated differences in titer in all the DENVax-4 strains are too 
small to be significant (Table 2.3). Like many biological assays, plaque assays have an 
inherently large standard deviation, and can range to +/-0.5log10PFU.  Although the graphs 
indicate a slight growth advantage of the DENVax-4b-P10 strain, these differences may not be 
significant.   
 
 
2.3.3 AMINO ACID CHANGES IN SEQUENCES 
!
DENVax-4-P10 genome sequencing showed mutations that corresponded to amino acids 
Envelope E417K and NS4A M17L. DENVax-4b-P10 genome sequencing showed a mutation 
that corresponded to amino acid Capsid C107Y.  The Envelope E417K mutation changes the 
amino acid residue so that a side chain with an amine group (NH2) is substituted for a side chain 
with a carboxyl group. The R group remains hydrophilic, but the residue is more basic and has a 
positive charge at neutral pH. The NS4A M17L mutation results in removal of a sulfate from the 
R group, but maintains non-polarity resulting in a hydrophobic amino acid. The Capsid C107Y 





Figure 2.4 Growth curves of DENVax-4 constructs during growth kinetics experiment. DENVax-4 and DENVax-4b passage 10 
viruses were tested for an increase in growth rate compared to1st generation DENVax-4. DENVax-2 was included as a control. The 
day each sample was taken is plotted on the x-axis and the titer is plotted on the y-axis. 
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Table 2.3 Average titers for DENVax-4-P10 and DENVax-4b-P10 growth curves. Titers are 
given in PFU/mL. Standard deviations were calculated using the titers of four replicates of each 
sample. 
!
 DENVax4b-P1 DENVax4b-P10 DENVax4 DENVax2 
Day Titer +/- Std Dev Titer +/- Std Dev Titer +/- Std Dev Titer +/- Std Dev 
2 3.22+/-0.16 2.68+/-0.34 3.15+/-0.16 5.51+/-0.27 
4 5.89+/-0.11 6.11+/-0.25 6.04+/-0.27 6.83+/-0.06 
6 6.80+/-0.53 6.24+/-0.42 6.41+/-0.23 6.63+/-0.19 
8 6.45+/-0.14 6.39+/-0.03 6.09+/-0.22 6.84+/-0.03 
10 6.51+/-0.10 6.68+/-0.09 6.03+/-0.24 6.90+/-0.10 





forming disulfide bonds, while tyrosine has a carbon benzene ring with a hydroxyl group. This 
causes the amino acid residue to become hydrophilic instead of hydrophobic, affecting its 
interaction with the other amino acid R groups. 
 
 
2.3.4 IMMUNOGENICITY IN AG129 MICE 
!
Samples taken on days 21 and 41 were analyzed by PRNT to determine neutralizing antibody 
response after a single immunization on day 0.  Sera samples from day 56 were analyzed to 
determine neutralizing antibody titers after boost on day 41. DENVax-4 first generation had the 
highest neutralizing antibody response on day 56 after immunization (Table 2.4). DENVax-4b-
P10 had the highest neutralizing antibody response on Day 21, but the response significantly 
decreased on Days 41 and 56. DENVax-4b-P1 had no significant neutralizing antibody titers 
after primary or secondary immunizations with titers not significantly different from the control 
FTA background titer levels. Because of possible introduction of inconsistencies during sample 
testing, the study was dismissed and further investigations into DENVax-4 modification were 












Table 2.4 Geometric mean titer (GMT) values of AG129 sera samples. Day 21 serology was 
completed to measure neutralizing antibody response after immunization on day 0. Day 56 
serology was completed to measure neutralizing antibody titers after immunization plus vaccine 
boost on day 42. GMT values were calculated by averaging the 50% neutralization dilution of 
each mouse in the group.  
!
 Day 21 Day 56 
 GMT +/- Standard Deviation GMT +/- Standard Deviation 
DENVax-4 44.4 +/- 11.4 285.1 +/- 187.1 
DENVax-4b-P1 44.4 +/- 39.5 35.6 +/- 82.1 
DENVax-4b-P10 160.0 +/- 105.5 78.2 +/- 66.0 











2.3.5 NEUTRALIZING ANTIBODIES IN NHP VACCINATED WITH DENVAX 
!
The evaluation of the second generation DENVax-4 viruses in NHP took place with a larger 
study testing immunization regimens.  I will focus on the groups immunized with the adapted 
vaccine strains described above.  The immunogenicity of DENVax-4b compared to that of 
DENVax-4 was tested. Groups 1 and 2 were vaccinated on day 0 with 2 doses and given no 
booster vaccination. Equivalent titers of either DENVax-4 or DENVax-4b were used. No 
significant differences in geometric mean titers (GMT) of neutralizing antibodies were found 
between any of the serotypes including DENV-4 (Figure 2.5). This suggests that using DENVax-
4b in tetravalent DENVax does not affect or increase the neutralizing antibody response against 
DENV-4.  
 
Neutralizing antibody responses in Groups 1 and 3 were compared to determine whether 
increasing the dose of DENVax-4 in tetravalent DENVax increased immunogenicity against 
DENV-4. Results showed that primates immunized with a higher dose of DENVax-4 showed an 
increase in GMT of primary neutralizing antibodies detected in the first 60 days compared to 
those immunized with traditional tetravalent DENVax (Figure 2.6). There was no significant 
difference in GMT between the other DENV serotypes. This suggests that a higher dose of 





Figure 2.5 Immunogenicity of DENVax-4-P10 and DENVax-4b-P10 in non-human primates. Vaccine formulations were 
tetravalent containing either first or second generation DENVax-4. GMT values are measurements of neutralizing antibody titers from 
Plaque Reduction Neutralization Technique with DENV-4. DENVax-4-P10 values (blue) and DENVax-4b-P10 values (red) were 





Figure 2.6 Immunogenicity of high dose and low dose DENVax in non-human primates. High dose tetravalent DENVax contains 
one log higher (106 PFU) DENVax-4 than low dose DENVax (105 PFU DENVax-4). DENVax-4 1st generation was used in this 
experiment. GMT values are measurements of neutralizing antibody titers from plaque reduction neutralization test with DENV-4. 





One of the frequent issues with developing a multivalent vaccine is ensuring that the vaccine 
provides significant immunogenicity against all targeted virus strains or stereotypes. This is often 
termed a “balanced immune response.”  DENVax contains 4 vaccine strains to protect against 
the four stereotypes of DENV that cause dengue fever. Three of the four stereotypes elicit a 
significant neutralizing antibody response in mice and provide protection upon challenge with 
wild type dengue virus. Data for DENVax-4 show a much lower immune response in mice. This 
suggests that the neutralizing antibody titers are much lower than those produced by the other 
DENVax strains, resulting in possible reduced seroconversion and protection from infection. 
Previous attempts to reengineer the DENVax-4 clone showed no increase in Vero cell growth 
kinetics. In this study we successfully performed blind serial passages on both the DENVax-4 
first generation clone and the DENVax-4b second generation clone. We also performed a growth 
kinetics analysis to observe any differences in peak titer between the passages. Finally, we 
completed sequencing of genomes of the first and tenth passages of each construct to note any 
mutations in the genomic RNA sequence. 
Both DENVax-4 and DENVax-4b were blindly passaged 10 times in Vero cells. During passages 
CPE was noted weekly on each cell flask. There were no significant differences in CPE noted, 
indicating sufficient attenuation in both the DENVax-4 and DENVax-4b passages. Samples from 
each flask were taken before subsequent passaging, and all samples were titrated at the 
conclusion of the serial passages. There was no significant difference in peak titer between the 
two viruses after passaging, and both had similar peak titer increases over the course of the 10 
weeks. This warranted further testing in Vero cells to determine growth kinetics because the  
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DENVax-4b strain had reached similar titers to that of DENVax-4, showing potential for an 
increased initial growth rate in vitro. 
 
A growth kinetics analysis in Vero cells was completed with samples of DENVax-4, DENVax-2, 
DENVax-4-P10 and DENVax-4b-P10. All four samples produced significant infectious titers in 
Vero cells. DENVax-2 reached the highest peak titer on day 4, and had the highest titer on day 
12. DENVax-4b-P10 reached the highest peak titer of the DENVax-4 clones tested, and also had 
the highest titer of the DENVax-4 clones on day 12. DENVax-4b-P10 also reached a higher titer 
on day 12 than DENVax-4. However, the differences between the titers of the DENVax-4 clones 
were not statistically significant. DENVax-4b did produce peak titers similar to that of DENVax-
4, which warranted testing in mice and non-human primates to determine if there is an increase 
in vaccine efficacy against DENV-4 between the two vaccine strains, since immunogenic protein 
structure also plays a role in immunogenicity. If DENVax-4b produced immunogenic proteins in 
the host that generated stronger neutralizing antibodies, the immunogenicity would increase 
compared to DENVax-4.  
 
Vaccine doses containing either DENVax-4 first generation or DENVax-4b-P10 were formulated 
and used to immunize AG 129 Mice and NHP. The neutralizing antibodies produced in the mice 
were not significantly different from the control values. No increase in antibody titer was noted 
in mice vaccinated with either DENVax-4b-P1 or DENVax-4b-P10. This suggests that the 




In the NHP study, neutralizing antibody responses were measured from each of the five groups 
to compare immunogenicity and test the effect of vaccine dose schedule, DENVax-4b-P10 
response versus DENVax-4 response, and increased DENVax-4 dose. The results of the NHP 
study suggested that second generation DENVax-4b-P10 did not result in improvement 
compared to DENV-4 neutralizing antibody responses. Increased DENVax-4 in the dose 
formulation did show a significant increase in neutralizing antibody production. Overall the 
results suggest that further modification of DENVax-4 was needed to improve immunogenicity, 
as the antibody response to DENV-4 did not improve with the new constructs.  
 
A successful DENV-4 vaccine should be able to elicit a response that adequately neutralizes 
multiple strains of wild type DENV-4 including newly evolved strains with genome 
modifications, different genotypes and different phenotypes. To date no studies have been done 
to test whether DENVax4 establishes an immune response against other DENV-4 strains. A 
future experiment with sera from this study will be to test neutralizing antibody response against 
multiple strains of DENV-4.  
 
The results described above indicate that increasing Vero cell adaptation of DENVax-4 by blind 
serial passaging was not effective in improving growth kinetics in Vero cells, specifically 
because there was no difference in peak titer between either DENVax-4-P1 and P10 or DENVax-
4b-P1 and P10. During genome sequencing there were three point mutations identified between 
passage 1 and passage 10 in both constructs. These mutations were located in the capsid region 
of DENVax-4b and in the prM and envelope genes of DENVax-4. Individually incorporating 
these mutations into the DENVax-4 or 4b backbones may provide increased growth in Vero cells 
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that was not conferred by all three together.  These mutations may also decrease the attenuation 
of the virus, which could improve immunogenicity in mice. A future experiment is to clone these 
mutations into the DENVax-4 or DENVax-4b construct, transcribe RNA and rescue live virus, 








3.1 BACKGROUND AND RATIONALE 
!
 
The use of live virus to vaccinate an individual is now a common practice in medicine. Vaccines 
containing live virus provide stronger long-term immunity against pathogens due to replication 
of virus within the host. To ensure the vaccinee develops no clinical symptoms of disease, the 
vaccine virus is significantly attenuated. The attenuating phenotypes of DENVax are reduced 
replication, temperature sensitivity, reduced neurovirulence, reduced plaque size and reduced 
ability for growth in mosquito cells to prevent vaccine virus transmission.  Inviragen’s current 
DENVax-4 strain used in DENVax contains prM and E genes from the wild type DENV-4 strain 
1036. During construction of DENVax-4 three clones were made. D2/4-P contains the prM and 
E genes from 1036 in a backbone of wild type DENV-2 16681.  D2/4-E contains prM and E 
genes from 1036 in a backbone of PDK-53 E variant, which has eight of the nine attenuating 
mutations in the PDK-53-V backbone. D2/4-V is the current DENVax4 clone, containing prM 
and E genes from 1036 in the PDK-53-V backbone. D2/4-P showed significant immunogenicity 
in AG129 mice after both primary immunization and boost, but also showed a 62.5 percent 
mortality rate, demonstrating that this strain is under-attenuated for use as a vaccine. D2/4-E also 
showed a significant increase in immunogenicity compared to D2/4-V after boost, and no 
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mortality resulted. However, D2/4-V elicited decreased neutralizing antibody titers and 
decreased immunogenicity in AG129 mice (Figure 3.1). This suggests that reverting select 
attenuating mutations in the PDK-53-V backbone to wild type DENV-2 sequence may increase 
the immunogenicity of DENVax-4 in mice.   
 
Of the nine attenuating mutations in the DENVax-2-PDK-53 backbone, three are silent 
mutations. It is understood that the three main attenuating mutations reside in the 5’UTR, NS1 
and NS3 (20). However, since the pD2/4-P and E strains showed higher immunogenicity in 
AG129 mice, reversion of one or more of these mutations may have an effect on DENVax-4 
fitness and thus boost its immunogenicity in vivo.  The hypothesis for this project is that 
reversion of noncritical attenuating mutations in the 5’ NCR, NS2A and NS4A genes to the wild-
type DENV-2 16681 sequence will increase immunogenicity of the vaccine strain in mice. Three 
candidate vaccine constructs have been generated based on this hypothesis. DENVax-4f contains 
reversion of the attenuating mutations in the NS2A and NS4A genes. DENVax-4g contains 
reversion of the attenuating mutations at 5’ NCR, NS2A and NS4A. DENVax-4j contains a 
reversion at the 5’ NCR. These three constructs were created by Claire Huang and Richard 
Kinney at the CDC in Fort Collins during the original cloning of DENVax-4. Since stocks were 







Figure 3.1 Immunogenicity of DENVax-3 and DENVax-4 chimeras in mice. D2/4-P and 
D2/4-E showed high neutralizing antibody titers after primary and secondary immunizations 
when compared to D2/4-V (DENVax-4). 
Huang C Y-H et al. (2003) Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent 










In addition to attenuating mutation reversions, new DENVax-4 constructs were designed that 
contained mutations found by serial passages of DENVax-4 first generation and DENVax-4b 
second generation in Vero cells (Figure 3.2). Blind serial passaging of viruses is a method used 
to select for increased in vitro growth rates, and increased growth rate may contribute to 
increased immunogenicity in mice. DENVax-4 and DENVax-4b were both blindly passaged 10 
times in Vero cells. Following passaging the genomes of the first and tenth passages of each 
virus was sequenced to compare viral genomes. DENVax-4b had one non-synonymous mutation 
in the capsid protein at position 107 which changed a cysteine to a tyrosine. DENVax-4 had two 
non-synonymous mutations, one in the envelope protein (position 417, glutamate to lysine) and 
one in the NS4A protein (position 17, methionine to leucine). Three new vaccine constructs were 
designed and created based on these sequencing results. DENVax-4e contains the capsid cysteine 
to tyrosine mutation in the DENVax-4b backbone. DENVax-4h contains the envelope 417 
glutamate to lysine mutation in the DENVax-4 backbone. DENVax-4i contains the NS4A 17 
methionine to leucine mutation in the DENVax-4 backbone.  
 
DENVax-4e, DENVax-4h, and DENVax-4i were cloned and amplified in Vero cells at 
Inviragen, and experiments done with these constructs were completed in conjunction with 
experiments done on DENVax-4f, DENVax-4g, and DENVax-4j provided by the CDC. All 
constructs were analyzed in vitro by performing growth curves in Vero cells to test for increased 
growth rate, and in C6/36 cells to test for decreased replication in cultured mosquito cells. Based 
on data from the growth curve analysis 3 constructs were selected and tested in AG129 mice to 





Figure 3.2 Schematic of DENVax-4 second generation constructs. Red triangles indicate attenuating mutations in the DENVax-2 
PDK-53 backbone. Blue triangles in the DENVax-4f, DENVax-4g, and DENVax-4j constructs indicate reversions to wild type 
sequence at the attenuating mutations.  
1 DENVax-4b contains modifications at the capsid/prM junction (blue). 
2 DENVax-4e contains a C to Y mutation at capsid 107 (arrow), and has a DENVax-4b backbone. 
3 DENVax-4h contains an E to K mutation at envelope 417, and has a DENVax-4 backbone. 
4 DENVax-4i contains an M to L mutation at NS4A 75, and has a DENVax-4 backbone.
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3.2 MATERIALS AND METHODS 
 
 
3.2.1 CLONING OF DENVAX-4E 
!
DENVax-4e was created using site-specific mutagenesis and molecular cloning techniques. 
Forward and reverse primers were designed using a sequence containing the necessary 
nucleotide mutation 3’ of the AgeI restriction site (Table 3.1). These primers amplified an insert 
flanked by the AgeI and MluI restriction sites in a PCR reaction. The template used was a 
pUC57 plasmid containing the region of DENVax4b plasmid between the AgeI and MluI sites 
(Figure 3.3). This construct was an intermediate from the previous DENVax4 modification 
study. The insert was digested with AgeI and MluI for 1 hour at 37ºC and purified using the 
GENECLEAN DNA purification kit (MP Biomedicals, Solon, OH). The ligation used T4 DNA 
ligase with 1:4 insert to vector ratio. The reaction was carried out at room temperature for 10 
minutes. The transformation used 2 !L of the ligation reaction and 50 !l XL-1 blue competent 
cells thawed on ice. Cells were incubated on ice with 2 !l of the ligation reaction for 30 minutes, 
heat shocked in a 42ºC water bath for 30 seconds, and placed on ice for 2 minutes. After 
transformation 450 !l 2xYT medium was added to the cells. Cells were then grown on a shaker 
incubator at 37ºC for 1 hour. Cells were then spread on 2xYT agarose plates containing 
ampicillin using glass beads and incubated overnight at 37ºC. Colonies were picked into 200 mL 
2xYT plus ampicillin medium the next morning and grown overnight to amplify cultures. 
Plasmids from large scale cultures were purified using a QIAfilter midi-prep kit (Qiagen, Hilden, 
Germany).The insert in the pUC57 intermediate was sequenced, and then removed using an 
AgeI/MluI digest. The insert was then ligated into the digested pD2/4b backbone, and amplified 





Table 3.1 Primers used in cloning of DENVax-4e and mutagenesis of DENVax-4h and DENVax-4i. Forward primer sequences 
are given 5’ to 3’. Reverse primer sequences are given 3’ to 5’. 
 
 pD2/4-e pD2/4-h pD2/4-i 
Forward 













Figure 3.3 Model of the modification to pD2/4-b to generate pD2/4-e. The reverse primer flanking the MluI site contained a 
nucleotide G to A change at position 416 to change the amino acid residue at capsid 107 to a tyrosine.
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3.2.2 PLASMID MUTAGENESIS CLONING OF DENVAX4H AND DENVAX4I 
!
DENVax-4h and DENVax-4i were generated using mutagenesis reactions in a QuikChange II 
XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA). Forward and 
reverse primers were designed that contained the desired mutation and flanked the same 
unmodified sequence on the pD2/4 template (Table 3.1). The kit contains a DNA polymerase 
that uses the primers to amplify the entire plasmid which contains the nucleotide mutation 
encoded by the primer (Figure 3.4). The PCR amplification reaction of the new plasmids 
contained 10x reaction buffer, 10 ng of the unlinearized DNA plasmid template, 125 ng of each 
primer, dNTP mix, and quik solution reagent to enhance amplification efficiency. The PCR 
consisted of 3 steps; 95ºC for 50 seconds, 60ºC for 50 seconds, and 68ºC for 13 minutes (1 
minute/ kb of plasmid). These steps were repeated for 18 cycles, followed by a single elongation 
step at 68ºC for 7 minutes. After PCR amplification DpnI enzyme was added to each reaction to 
digest the template plasmid. The mutated plasmid was not digested because DpnI enzyme targets 
methylated DNA found on the template plasmid but not the mutated plasmid. The reaction was 
digested for 1 hour at 37ºC. During this time XL-10 gold super competent cells were thawed on 
ice, and prepared for transforming by supplementation with beta-ME solution to improve 
transformation efficiency and stability of the plasmid. Beta-ME solution was added to the 
competent cells and incubated for 10 minutes. After DpnI digestion was completed 2 !l of each 
reaction was added to 45 !l of XL-10 gold cells and tapped to mix. Transformation reactions 
were incubated on ice for 30 minutes, heat shocked in a 42ºC water bath for 30 seconds, and 
incubated on ice for 2 minutes. During the incubations NZY+ medium was prewarmed to 42ºC 





Figure 3.4 Model depicting the cloning method for DENVax-4h and DENVax-4i. The DNA polymerase (PfuUltra high-fidelity) 
used to amplify the infectious clones has an 18-fold higher fidelity than Taq DNA polymerase. Plasmids are amplified in Xl-10 gold 
ultra-competent E. coli cells, which have a 5-fold increase in transformation efficiency than XL1-blue cells, as well as an Hte 




digested by DpnI and then the mutated plasmid was transformed into XL10-gold super 
competent cells, which have been optimized to grow unstable plasmids. A pWhitescript control 





Full sequencing of the DENVax-4h and DENVax-4i plasmids was necessary as a result of 
completely new plasmid construction, and was completed after amplification. Primers were 
designed using previous records from scientists at the CDC on DENVax-4 plasmid sequencing, 
and ordered from Life Technologies. Sequencing reactions were performed by Beckman Coulter 
Genomics. Sequencing of the modified insert in the DENVax-4e plasmid was also completed by 
Beckman Coulter Genomics. Chromatograms were analyzed using Finch TV (Geospiza Inc., 
Seattle, WA) and CLC Sequence Viewer Software (CLC bio, Aarhus, Denmark). Full scale 
plasmid sequencing was not necessary because the DENVax-4e plasmid backbone is from the 




3.2.4 RNA TRANSCRIPTION 
!
RNA was transcribed from each of the three plasmids using an ampliscribe kit (Epicentre 
Technologies, Madison, WI). The plasmid DNA templates for each construct were linearized by 
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XbaI digestion and purified using a GENECLEAN DNA purification kit. To promote efficient 
capping of the mRNA, the concentration of ATP in the dNTP mix was reduced by 1/5, and 200 
ng of digested template DNA was used. The reaction was performed at 37ºC for 2 hours, and 
then placed on ice before electroporation. 
 
 
3.2.5 CELL CULTURE 
!
Vero cells are mammalian cells derived from African green monkey kidney. The Vero cell line 
used in the in vitro experiments was obtained from the Waisman Cell Bank (Waisman 
Manufacturing, Madison, WI). Vero cells were grown at 37ºC in Dulbecco’s Modification of 
Eagle’s Medium (DMEM, Mediatech Inc., Manassas VA) supplemented with 10% fetal bovine 
serum (FBS, Hyclone, Logan UT), 2% L-glutamine (Hyclone), and 1% penicillin-streptomycin 
(Pen-Strep, Hyclone). To passage the cells Tryple Express solution (Life Technologies, Grand 
Island NY) was used to remove the cells from the flask surface. Cells were diluted 1:24 for 
passage once a week, and passaged 20 times before new cells were thawed.  
C6/36 cells are Aedes albopictus mosquito cells that were obtained from stocks at the CDC and 
grown in DMEM supplemented with 10% FBS, 2% L-glutamine, 1% pen-strep, 1% Non-
essential amino acid solution (Life Technologies, Carlsbad, CA), and 1% sodium pyruvate 
solution (Mediatech Inc., Manassas, VA). Cells were grown at 28ºC, and scraped off flask 
surface for passaging using rubber cell scraper, and diluted 1:24 for passaging every week. After 





After RNA transcription the reaction mix was transferred to an electroporation cuvette 
containing 400 !l Vero cells at 1x107 cells/mL. A BTX ECM 830 electroporater from Harvard 
Apparatus was used. The electric pulse was 225V for 25 msec. Cells were then transferred to an 
eppendorf tube and incubated at room temperature for 10 minutes. The mix was then transferred 
to a flask containing DMEM 5% FBS and incubated at 37ºC overnight. Medium was changed 
after 24 hours to remove cell debris. 
 
 
3.2.7 VIRUS AMPLIFICATION 
!
Virus was grown in flasks containing the electroporated cells for 12 days. The virus-containing 
media was harvested on day 12 and stored at -80°C. Two mL of each virus stock was adsorbed to 
a new Vero monolayer on a T-75 flask for 60 minutes with rocking to prevent drying of the cells. 
After adsorption 10 mL of DMEM 2% FBS was added to each flask. Flasks were incubated for 
12 days and the medium was harvested and stored at -80C. This generates the passage 2 (P2) 







3.2.8 IN VITRO GROWTH KINETICS  
!
Growth curves for each of the new DENVax-4 constructs were done in Vero cells to assess peak 
titer in comparison to DENVax-4. Vero T-75 flasks were seeded 2 days prior to infection. Flasks 
were infected at a MOI of 0.001 with P2 of each of the DENVax constructs. DENVax-4, 
DENVax-2, and 1036 wild type DENV-4 were used as controls. Growth medium, DMEM 
without FBS, was changed on days 2, 4, and 6-12. Flasks were washed 2 times with PBS during 
medium changes. Viruses were grown for 12 days, and samples were taken on days 2 and 4-12 
for plaque titration by IFA. Growth curves for each construct including the controls were done in 
duplicate; two flasks per construct. 
 
Growth curves were also conducted using C6/36 cells to test for decreased replication and 
increased attenuation when compared to wild type DENV-4 1036 and DENVax-4. C6/36 T-75 
flasks were seeded 2 days prior to infection. Flasks were infected at a MOI of 0.001 with P2 of 
each of the DENVax constructs. DENVax4, DENVax2, and 1036 wild type dengue 4 were used 
as controls. Growth medium was DMEM without FBS, and was changed on days 2, 4, and 6-12. 
Flasks were washed 2 times with PBS during media changes. Viruses were grown for 12 days, 
and samples were taken on days 2 and 4-12 for plaque titration by IFA. Growth curves for each 







3.2.9 IMMUNOFOCUS ASSAY  
!
To assess virus titer, growth curve samples were analyzed by an immunofocus assay instead of a 
traditional plaque titration done in previous studies. Several issues arose with identifying plaques 
using neutral red solution because the clarity depends heavily on the quality of the batch of 
neutral red used. The immunofocus assay is an antigen staining technique allowing for 
visualization of virus-infected cell foci on the Vero monolayer. Virus samples were adsorbed to 
Vero monolayers pre seeded on 6-well plates for 90 minutes with rocking every 8 minutes. After 
adsorption wells were over-laid with a 1:1 solution of 1.4% carboxymethyl cellulose (CMC) and 
2x DMEM containing 2% FBS. Plates were incubated for 7 days, and then the wells were 
washed 3 times with PBS to remove the CMC. Cells were fixed using 1 mL per well of cold 
methanol and incubated at -20ºC for approximately 20 minutes in Ziploc bags. After fixing the 
methanol was removed and plates were air dried in a chemical fume hood for approximately 40 
minutes. Wells were then washed with PBS. The primary antibody was a mouse monoclonal 
antibody against DENV-4whose target has not been mapped. The stock antibody was diluted 
1:2000 in a blocking buffer solution containing 2.5% dry milk and 0.5% tween-20 in PBS. 
Primary solution was added at 1 mL per well. Plates were incubated overnight at 4ºC. Primary 
antibody was then removed and wells washed 2 times with wash buffer. Secondary antibody was 
anti-mouse serum from goats conjugated with horse radish peroxidase (HRP) (Southern 
Biotechnologies, Birmingham, AL). The secondary antibody was diluted 1:1000 in blocking 
buffer and added 0.5 mL per well. Plates were incubated at 37ºC for 1 hour. Wells were washed 
2 times with wash buffer and 350 !l per well of substrate was added. Plates were incubated at 
room temperature until foci were visible, approximately 30 minutes. Wells were then washed 
once with distilled H2O to stop the reaction. Plates were inverted and left to dry for 24 hours, 
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after which foci were counted. Titers were calculated by multiplying the number of foci in the 
well by the dilution factor. 
 
 
3.2.10 AG129 MOUSE STUDY 
!
To test the efficacy of the second generation DENVax-4 constructs the AG129 mouse model was 
used. AG 129 mice are deficient in interferon alpha, beta, and gamma receptors (58). As a result 
interferon, which has an important role in the DENV immune response in humans, cannot affect 
the immune response in mice. This makes AG129 mice a good small animal model for DENV 
vaccine development because they show clinical symptoms when infected AG129 mice were 
vaccinated with either DENVax-4 1st generation, DENVax-4e, DENVax-4f, DENVax-4h, or 
PBS control. Six animals approximately 4 weeks of age were used in each group. Mice received 
primary vaccinations on day 0 and bled on day 0, day 42, and day 56 to measure neutralizing 
antibodies. On day 56 mice were challenged with wild type DENV-2. Mice were bled on day 3 
and day 59 to test for viremia post-immunization and post-challenge. Morbidity and mortality 
were monitored for the duration of the study. The mice were vaccinated and challenged at 
Inviragen in Madison, WI. Serology analysis was completed at Inviragen in Fort Collins, CO.  
 
3.2.11 MICRONEUTRALIZATION ANALYSIS 
!
To measure neutralizing antibody response in mouse sera, a microneutralization assay was used. 
On day -1 Vero cells were seeded on 96-well plates for day 0 confluence. On day -1 sera/virus 
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dilutions were also prepared for overnight incubation. Sera samples were diluted 2-fold in 
DMEM supplemented with 2% FBS, 2% L-glutamine, and 1% Pen-strep. The starting dilution of 
mouse sera was 1:20. After dilutions were completed approximately 240 PFU of DENV-4 1036 
were added per well. Dilution plates were incubated overnight at 4ºC for approximately 18 
hours. On day 0 medium was aspirated off Vero 96-well plates and 30!l of a dilution was added 
to each well. Virus/sera dilutions were adsorbed to the monolayers for 90 minutes, then wells 
were overlaid with a 1:1 ratio of 1.4% methyl cellulose and 2x DMEM supplemented with 4% 
FBS. Plates were incubated at 34ºC for 48 hours. After virus replication methyl cellulose overlay 
was removed and wells were washed once with PBS. Monolayers were then fixed with cold 
methanol and incubated at -20ºC for approximately 90 minutes. After fixing methanol was 
removed and plates were air dried. Plates were then washed 1x with wash buffer. Primary 
antibody diluted 1:1000 in milk blocking solution was then added at 50 !l per well. Plates were 
incubated overnight at 4ºC for approximately 18 hours. Primary antibody was then washed off 
the wells using wash buffer. Secondary antibody was diluted 1:200 in milk block solution and 
was added at 50 !l per well. Plates were incubated at 37ºC for approximately 1 hour. During this 
time the substrate was prepared by dissolving 1 3-amino-9-ethlycarbazole (AEC) tablet in 2.5 ml 
of dimethyl sulfoxide (DMSO). Once dissolved 47.5 ml of 50 mM acetate buffer was added to 
make 50 ml of substrate. After incubation secondary antibody was washed off the plates using 
wash buffer. To complete the substrate solution 250 !l 3% hydrogen peroxide was added. The 
solution was mixed and then 50 !l per well was added. Plates were incubated at room 
temperature for 20 minutes to ensure full development of red foci. Plates were then washed with 
tap water and dried overnight. Foci were counted using an Elispot plate reader (Autoimmun 
Diagnostika, Strassberg, Germany). 
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3.2.12 PLAQUE SIZE ANALYSIS 
!
To test for attenuation in vitro, measurements of viral plaques were taken and compared to wild 
type DENV-4 1036 plaques. On day -2, Vero cells were seeded on 6-well plates to ensure 
confluence. On day 0 Viruses were diluted in serial 10-fold dilutions in DMEM supplemented 
with 2% FBS, 1% L-glutamine, and 1% Pen-Strep. Medium was aspirated off the Vero cell wells 
and a 100 !L sample of virus dilution was added. Virus was adsorbed to the monolayers for 90 
minutes with rocking every 8 minutes to prevent drying. After adsorption wells were overlaid 
with 4 mL per well 1:1 solution of 1.6% agarose gel and BSS (NaCl, KCl, NaH2PO4-H2O, 
glucose, CaCl2-2H2O, MgSO4-7H2O). Plates were incubated at 37ºC for 4 days, then overlaid 
with 2 mL per well of 1:1 BSS/1.6% agarose solution supplemented with neutral red. Plaques 
were measured on days 5, 6, and 7. Ten plaques were measured for each construct and the 
diameters were averaged. A student t-test was done to determine the significance of the size 






3.3.1 GENERATION OF DENVAX-4E PLASMID 
!
The DENVax-4e plasmid was made using a fragment from DENVax-4b. The fragment was 
flanked by the AgeI and MluI restriction enzyme sites, and was purified by gel electrophoresis 
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after digesting the DENVax-4b plasmid with AgeI and MluI. The DNA fragment was cut from 
the gel and cleaned using the GENECLEAN kit. After purification the fragment was used as a 
PCR template and amplified using a primer that contained the desired nucleotide mutation. After 
PCR amplification the insert contained the mutated sequence that introduces a C-Y mutation at 
amino acid 107 in the capsid sequence. This insert was ligated into a pUC-57 intermediate and 
amplified in DH5- alpha E. coli competent cells. Colonies picked were grown in LB/AMP media 
overnight and then plasmids were purified using a Qiagen Mini-Prep kit. The insert region of the 
plasmid was sequenced to confirm that the desired mutation had been introduced into the insert 
that had been amplified. The intermediate plasmids and the DENVax-4b full length plasmid were 
digested with AgeI and MluI. The DENVax-4b vector and insert from intermediate plasmid were 
purified by gel electrophoresis and cleaned using the GENECLEAN kit. The insert was then 
ligated into the vector and transformed into XL-1 blue E. coli competent cells. Colonies grown 
on 2xYT plates were amplified in 2xYT/AMP media and plasmids were purified using a Qiagen 
Midi-Prep kit. The full length plasmid was sequenced upon purification. 
 
 
3.3.2 GENERATION OF DENVAX-4H AND DENVAX-4I PLASMIDS 
!
Infectious cDNA clone bacterial DENVax plasmids are large and very unstable when 
transformed into competent cells. It is common for large deletions to occur in the plasmid due to 
the difficulty to replicate the plasmid. IC DENVax plasmids also result in reduced cell viability. 
As a result the only colonies will either be small with full length IC plasmids or healthy with 
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plasmids containing deletions. Previous DENVax cloning used XL-1 blue competent E. coli cells 
because of their known stability with large plasmids. Traditional cloning methods as described 
above were first used in the DENVax-4h and DENVax-4i cloning, but transformation attempts in 
XL-1 blue cells produced no colonies or plasmids with deletions. A new cloning procedure was 
developed that involved the use of a plasmid mutagenesis kit purchased from Agilent 
Technologies. A high efficiency DNA polymerase was used to generate full length IC DENVax-
4 plasmids using two primers containing the desired nucleotide mutation for each construct. This 
encoded the desired nucleotide mutations to make DENVax-4h or DENVax-4i. Upon synthesis 
the template plasmid was degraded using DpnI enzyme. The plasmids were transformed into XL-
10 gold E. coli competent cells. These cells are designed to allow for replication of large unstable 
plasmids. The colonies were grown on LB/AMP plates and picked into LB/AMP media for 
overnight amplification. Because of the high replication efficiency of these cells only 3 mL 
cultures were grown. Plasmids were purified using a Qiagen Mini-Prep kit. The full length 
plasmid for each construct was sequenced. 
 
 
3.3.3 VIRUS RESCUE AND AMPLIFICATION 
!
Each full length plasmid was digested with XbaI to linearize the DNA, which was then 
transcribed into full length genomic RNA. After RNA transcription the RNA was electroporated 
into Vero cells for virus production. Virus was grown on Vero cells for 12 days before harvest. 
This yielded passage 1 of each new construct (DENVax-4e, DENVax-4h, and DENVax-4i). 
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Vero cells seeded 2 days prior to passage 1 harvest were infected with passage 1 samples of each 
virus to generate passage 2. DENVax-4e-P2 was harvested 5 days after infection because the 
monolayer was showing severe cell detachment. DENVax-4h-P2 and DENVax-4i-P2 were 
harvested 7 days after infection for the same reasons.  
 
 
3.3.4 PHENOTYPIC CHARACTERIZATION IN VERO CELLS 
!
A growth curve analysis in Vero cells was done for each of the modified DENVax-4 clones to 
compare growth efficiency and peak titer to DENVax-4 first generation (Figure 3.5). Controls 
used in the growth curves were DENVax-4 and DENVax-2. Each construct was grown in 
duplicate flasks for data comparison. Wild type 1036 virus reached the highest peak titer on day 
6. DENVax-4e reached the highest peak titer of the DENVax-4 constructs on day 6. DENVax-4i 
reached the lowest peak titer of the DENVax-4 constructs on day 6. All viruses reached a similar 





Figure 3.5 Growth Kinetics of DENVax-4 constructs in Vero cells. Constructs were grown on Vero cells for 12 days. Samples 
taken on designated days were titrated by immunofocus assay. 
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3.3.5 ATTENUATION CHARACTERIZATION IN C6/36 CELLS 
!
A growth curve analysis was done in C6/36 cells to test for decreased replication in mosquito 
cells (Figure 3.6). Wild type DENV-4 1036 reached the highest peak titer on day12. DENVax-4 
reached the highest peak titer of the DENVax-4 constructs. DENVax-4f reached a significantly 
lower peak titer than the other DENVax-4 constructs, and did not show detectable virus growth 
until day 8. DENVax-4e, DENVax-4, 1036, DENVax-4i, and DENVax-4j showed virus 
production at day 2. DENVax-4g and DENVax-4h showed virus production on day 4. All 
constructs showed increasing titers through day 12. 
 
 
3.3.6 IMMUNOGENICITY IN AG129 MICE 
!
Based on the growth kinetics analysis done in Vero and C6/36 cells, 3 constructs were tested 
against DENVax-4 for an increase in immunogenicity in mice. DENVax-4e and DENVax-4h 
were selected based on their high peak titers in Vero cells. DENVax-4f was selected because of 
the significant decreased peak titer in C6/36 cells (Table 3.2). Mice were immunized with a 10^5 
PFU/mL dose on day 0. Serology was done on samples taken day 45, day 56, and day 71 using a 
microneutralization assay. To interpret the data geometric mean titer (GMT) values were 
analyzed. These values indicate the dilution of mouse serum containing sufficient antibodies to 





Figure 3.6 Growth kinetics of DENVax-4 constructs in C6/36 cells. Constructs were grown in C6/36 mosquito cells for 12 days. 
Samples taken on designated days were titrated by immunofocus assay. DENVax-4f and DENVax-4g had no IFU formation before 




Table 3.2 Viral titers of DENVax-4 constructs tested in mice. Standard deviations were 
calculated using titers from duplicate flasks. 
DENVax-4e  
Vero C6/36 
Day Log10 IFU/mL +/- Standard Deviation Log10 IFU/mL +/- Standard Deviation 
2 3.64+/- 0.18 2.01+/- 0.19 
4 6.01+/- 0.08 2.32+/- 0.14 
6 7.63+/- 0.02 3.93+/- 0.14 
8 6.49+/- 0.07 5.38+/- 0.03 
10 6.70+/- 0.04 6.44+/- 0.04 
12 6.43+/- 0.09 7.30+/- 0.15 
DENVax-4f  
Vero C6/36 
Day Log10 IFU/mL +/- Standard Deviation Log10 IFU/mL +/- Standard Deviation 
2 2.40+/- 0.03 NOT DETECTED 
4 4.89+/-0.19 0.40+/-0.35 
6 7.26+/-0.05 1.74+/-0.04 
8 6.83+/-0.08 2.81+/-0.11 
10 6.98+/-0.02 3.49+/-0.15 
12 6.58+/-0.03 3.98+/-0.20 
DENVax-4h  
Vero C6/36 
Day Log10 IFU/mL +/- Standard Deviation Log10 IFU/mL +/- Standard Deviation 
2 3.77+/-0.04 1.86+/-0.08 
4 6.38+/-0.05 2.49+/-0.02 
6 7.46+/-0.05 4.26+/-0.02 
8 6.40+/-0.04 5.91+/-0.09 
10 6.81+/-0.02 7.18+/-0.18 
12 6.11+/-0.02 7.92+/-0.02 
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value is calculated by counting foci in virus-infected wells containing no sera. Half of this value 
is the 50% cutoff amount, and the highest dilution of mouse serum containing equal or fewer foci 
is the value used to calculate the GMT. GMT values for each group in the study were calculated 
by first taking the GMT of the replicates of each mouse, and then taking the GMT of those 
values of all the mice in the group. P-values were calculated using a student’s t-test with a one-
tailed distribution and two variables with unequal variance.  
DENVax-4 elicited a 50% plaque reduction rate at a 1:100 serum dilution on day 45 with a GMT 
of 100 (Figure 3.7). This increased on day 56 to a GMT of 132. DENVax-4f had a 50% plaque 
reduction rate at approximately 1:100 serum dilution on day 45, which increased to 1:126 on day 
56. This suggests that DENVax-4f does not provide a significant increase in immunogenicity 
when compared to DENVax-4. DENVax-4e had a 50% plaque reduction rate at approximately 
1:183 serum dilution on day 45, with a GMT of 183. The GMT increased to 201 on day 56. The 
p-value for this when compared to DENVax-4 was 0.04 on day 45 and 0.065 on day 56, showing 
that the difference on day 45 is statistically significant (Table 3.3). Therefore, DENVax-4e had 
increased immunogenicity in AG129 mice after a single dose to a greater extent than DENVax-4. 
DENVax-4h had a 50% plaque reduction rate at 1:200 serum dilution. This is a two-fold increase 
in immunogenicity compared to first generation DENVax-4. On day 56 DENVax-4h had a GMT 
of 242. The p-values for DENVax-4h on day 45 and day 56 were 0.01 and 0.027 respectively, 
showing that the data was statistically significant when compared to DENVax-4. The GMT 
values on day 45 and day 56 for DENVax-4f were close to DENVax-4, and the p-values of 0.33 
(day 45) and 0.34 (day 56) showed that the values were not statistically significantly different 






Figure 3.7 Plot depicting GMT values in AG129 mice at Day 45 and Day 56. The error bars represent the standard deviation of the 




Table 3.3 Average GMT values and p-values showing significant differences from DENVax-
4. Asterisks mark p-values that are lower than 0.05 and have a confidence interval of 90% or 
greater. 
Vaccine Construct GMT Day 45 T-Test GMT Day 56 T-Test 
0.50 0.50 
DENVax-4  
































Mouse mortality was also monitored for the duration of the study. FTA control mice died from 
infection approximately 3-4 days after DENV-2 challenge on day 56 (Figure 3.8). Mice 
vaccinated with DENVax-4, DENVax-4e, DENVax-4f, and DENVax-4h survived DENV-2 
challenge. DENVax-4f and DENVax-4h vaccinated groups each had one mouse succumb to 
neurovirulence infection approximately 18 days after DENV-2 challenge. Two DENVax-4 
vaccinated mice succumbed to neurovirulence approximately 20 days after DENV-2 challenge. 
All remaining mice were euthanized on day 90. 
 
 
3.3.7 PLAQUE SIZE 
!
Plaque size is a phenotype used to determine attenuation of a virus. Wild type DENV-4 1036 
was used as a control in this experiment, and had an average plaque size of 3.45 mm. All the 
DENVax-4 second generation constructs had smaller plaque diameters than 1036, indicating an 
attenuated phenotype (Figure 3.9 and Figure 3.10). DENVax-4e had the smallest plaque size of 
0.7 mm, followed by DENVax-4f (1 mm) and DENVax-4h (1.1 mm.). DENVax-4g had the 






Figure 3.8 Mortality rate of DENVax-4 vaccinated AG129 mice. Mice were challenged on day 56 with DENV-2. There were six 
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Figure 3.10 Plaque phenotypes of DENVax-4 2nd generation constructs. DENV-4 1036(A), 
DENVax-4 (B), DENVax-4j (C), DENVax-4i (D), DENVax-4h (E), DENVax-4g (F), DENVax-





Modified live vaccines are used because they often generate a more robust and long-lasting 
immune response in the host to provide greater protection against pathogen infection. In order to 
generate this significant immune response the virus must be able to replicate efficiently in the 
host to stimulate the immune system, but also replicate inadequately so clinical symptoms don’t 
develop. Because of the decreased immunogenicity induced by Inviragen’s current DENV-4 
vaccine strain, modification is needed to increase growth efficiency in the host in order to 
generate significant antibody titers. Based on data from previous attempts to reengineer 
DENVax-4, 6 new potential vaccine constructs were cloned and amplified. All the constructs 
were tested for improved growth kinetics in Vero cells, decreased replication in C6/36 cells. 
Phenotypic characterization was done using plaque size and growth kinetics. Genetic 
characterization was done by full viral RNA genome sequencing.  
DENVax-4e, DENVax-4h and DENVax-4i cDNA were successfully cloned, transcribed to 
infectious RNA, electroporated, and replicated to produce virus in Vero cells. Unlike DENVax-
4, passage 2 of these three constructs had to be harvested before the predicted day12 due to 
complete detachment of the Vero monolayer. DENVax-4e was harvested on day 5 and DENVax-
4h and DENVax-4i were harvested on day 7. This indicates that these constructs have a 
significantly increased growth rate in Vero cells than DENVax-4. However, during the Vero 
growth kinetics analysis DENVax-4e and DENVax-4h reached similar peak titers to DENVax-4 
on day 6. DENVax-4i reached a lower peak titer on day 6 compared to DENVax-4, but reached a 
similar final titer on day 12. All 3 constructs also reached similar titers to DENVax-4 in C6/36 
mosquito cells, showing reduced growth rate compared to DENV-4 1036. DENVax-4e and 
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DENVax-4h also had significantly decreased plaque size compared to wild type DENV-4 1036, 
which is an indicator of attenuation. 
DENVax-4f, DENVax-4g, and DENVax-4j were generated at by scientists at the CDC. 
DENVax-4f and DENVax-4g were amplified on Vero cells at Inviragen due to minimal stock. 
All 3 constructs reached similar titers to DENVax-4 on day 12 in the Vero growth kinetics. 
However, DENVax-4f had reduced growth rate in Vero cells compared to the other constructs. In 
C6/36 cells DENVax-4f showed significant attenuation and decreased replication rate compared 
to the other DENVax-4 constructs, reaching a peak titer of approximately 1e4 PFU/mL after 
twelve days. The titers of DENVax-4g and DENVax-4j were comparable to DENVax-4. 
 Because of limited mouse availability only 3 new DENVax-4 constructs were inoculated into 
mice. DENVax-4e and DENVax-4h were selected because of their similar peak titer values to 
DENVax-4 in both Vero and C6/36 cells. DENVax-4f was selected because of the significant 
attenuation shown in C6/36 cells. In AG129 mouse study DENVax-4 was used as a positive 
control and FTA was used as a negative control. After a single vaccine dose DENVax-4e and 
DENVax-4h elicited significantly increased neutralizing antibody responses on day 45 compared 
to DENVax-4. DENVax-4h also elicited significantly increased neutralizing antibody titers on 
day 56 compared to DENVax-4. This suggests that further testing of DENVax-4h should be 
completed. Future experiments include preparing a tetravalent formulation of DENVax 
containing DENVax-4h and testing in AG129 mice, as well as testing monovalent and tetravalent 
formulations in non-human primates.  
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To increase immunogenicity of DENVax-4, we used blind serial passaging of the current 
DENVax-4 construct and DENVax-4b second generation construct to generate two new 
DENVax-4 candidates; DENVax-4-P10 and DENVax-4b-P10. DENVax-4b has a different 
secondary RNA structure than DENVax-4 because of the modifications at the capsid/prM 
junction (data not shown) (RNAstructure, University of Rochester). Modifying the sequence to 
be more like DENV-4 instead of DENV-2 would theoretically increase immunogenicity against 
wild type DENV-4 infection. However DENVax-4b did not show an increase in Vero growth 
rate even after Vero cell adaptation, indicating further reengineering of DENVax-4 is needed. 
 
Sequencing of the genomes from passages 1 and 10 for DENVax-4 and DENVax-4b revealed 
two amino acid changes in DENVax-4-P10 (Envelope E417K and NS4A M17L) and one amino 
acid change in DENVax-4b-P10 (Capsid C107Y). We attempted to optimize DENVax-4 and 
DENVax-4b by successfully cloning each of these mutations into DENVax-4 or DENVax-4b 
cDNA to investigate the potential of each of the adaptive mutations for increased growth 
efficiency in Vero cells. Replication rate in cell culture is an indicator of replication efficiency in 
the host, which is an important factor in production of neutralizing antibodies. Growth kinetics in 
Vero cells showed comparable maximum titer to DENVax-4, but higher early growth kinetics 
was demonstrated in several constructs including DENVax-4e and 4h. As such we tested we 
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further investigated the immunogenicity of these constructs in AG129 mice. Vaccination in 
AG129 mice showed an approximately 2-fold increase in immunogenicity in DENVax-4h and an 
approximately 1.5-fold increase in DENVax-4e.  
 
The envelope protein provides epitopes for neutralizing antibodies, and modifying the sequence 
to optimize epitope sites for antibody binding to prevent envelope fusion with the endosome 
would possibly increase immunogenicity. The envelope mutation in DENVax-4h at position 417 
is in the conserved portion in the stem region (Figure 4.1). DENV-4 has a different amino acid in 
this position compared to other flaviviruses. The stem region is in domain III of the E protein 
where the strongest neutralizing epitope sites exist. Antibodies that bind and neutralize this site 
prevent the stem region from fusing with the endosome membrane after endocytosis. This is 
especially important when virus/antibody complexes are taken up by Fc! receptor-bearing cells. 
Non-neutralized virions endocytosed by Fc! receptor-bearing cells is the hypothesis behind 
antibody dependent enhancement, so strong neutralizing antibodies at this site are critical. 
However, further investigation needs to be done to test this relationship.  
 
The DENVax-4e Capsid C107Y mutation is located in a cleavage site just before a 
transmembrane segment that spans the endoplasmic reticulum membrane in the host cell. During 
viral replication the capsid protein is cleaved from this transmembrane segment by the viral 
protease (30). The rate of this cleavage affects the rate of cleavage of the prM protein from this 
segment, and thus affects the rate of virus assembly. Cysteine contains an SH group that can 





Figure 4.1 Map of Dengue E protein domains showing a conserved region of each dengue 
serotype and west nile virus (WNV). Domain I is red, Domain II is yellow, and Domain III is 
blue. The fusion loop is at position 98-107. 
 
Schmidt AG et al. (2010) Peptide Inhibitors of Dengue-Virus Entry Target a Late-Stage Fusion 
Intermediate. PLoS Pathogens 6(4): e1000851 
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prevent disulfide bonds from forming, resulting in more efficient cleavage of the capsid and 
increased rate of virus assembly.  
 
Improvements in Vero growth kinetics and possible improvements in immunogenicity of 
DENVax-4e and DENVax-4h warrants further investigation in mouse models utilizing a 
challenge with more than one DENV-4 isolates.  Positive results would then warrant further 
testing in non-human primates. Tetravalent DENVax formulations containing either DENVax-4e 
or DENVax-4h should be tested in mice and non-human primates to compare immunogenicity 
and possible cross reactivity with the other DENVax strains. Full viral genome sequencing of 
DENVax-4e and DENVax-4h should be completed, and constructs should be genotypically 
isolated by plaque purification to select for clonal populations. 
 
While current DENVax-4 provides sufficient immunogenicity to protect from infection, it is 
necessary to continue to adapt this vaccine strain to improve neutralizing antibody titers. Future 
studies also need to test the ability of DENVax-4 to elicit antibodies that neutralize multiple 
currently circulating strains of DENV-4. Weak or non-neutralizing antibodies can result in ADE. 
A dengue vaccine needs to generate long lasting neutralizing antibodies that can protect against 








1. Chambers TJ et al. (1990) Flavivirus genome organization, expression, and replication. 
Annual Review of Microbiology 44: 649-688. 
2. Welsch S et al. (2009) Composition and Three-Dimensional Architecture of the Dengue 
Virus Replication and Assembly Sites. Cell Host and Microbe 5:365-375. 
3. Gutsche I et al. (2011) Secreted dengue virus nonstructural protein NS1 is an atypical 
barrel-shaped high-density lipoprotein. PNAS 108(19): 8003-8008 
4. Limjindaporn T et al. (2009) Interaction of dengue virus envelope protein with 
endoplasmic reticulum-resident chaperones facilitates dengue virus production.  
Biochemical and Biophysical Research Communications 379: 196-200. 
5. Butrapet S et al. (2011) Amino acid changes within the E protein hinge region that affect 
dengue virus type 2 infectivity and fusion. Journal of Virology 413: 118-127. 
6. Guzman MG et al. (2010) Dengue: a continuing global threat. Nature Reviews 
Microbiology: S7-S16. 
7. Lin C-F et al. (2006) Autoimmune Pathogenesis in Dengue Virus Infection. Viral 
Immunology 19(2): 127-132. 
8. Fink J et al. (2006) Role of T cells, cytokines, and antibody in dengue fever and dengue 
hemorrhagic fever. Review of Medical Virology 16: 263-275. 
9. Hsieh S-C et al. (2011) The C-terminal helical domain of dengue virus precursor 
membrane protein is involved in virus assembly and entry. Virology 410: 170-180. 
10. Murphy BR et al. (2011) Immune Response to Dengue Virus and Prospects for a 
Vaccine. Annual Review of Microbiology 29: 587-619. 
11. Johansson MA et al. (2011) Models of the impact of dengue vaccines: A review of 
current research and potential approaches. Vaccine 29: 5860-5868. 
12. Guy B et al. (2011) From research to phase III: Preclinical, industrial, and clinical 
development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29: 7229-7241. 
13. Anderson KB et al. (2011) Interference and Facilitation Between Dengue Serotypes in a 
Tetravalent Live Dengue Virus Vaccine Candidate. Journal of Infectious Diseases 204: 
442-450. 
14. Thomas SJ et al. (2011) Critical issues in dengue vaccine development. Current Opinion 
in Infectious Diseases 24: 1-9 
88 
!
15. Murrell S et al. (2011) Review of dengue virus and the development of a vaccine. 
Biotechnology Advances 29: 239-247. 
16. Osorio JE et al. (2011) Development of DENVax: A chimeric dengue-2 PDK-53-based 
tetravalent vaccine for protection against dengue fever. Vaccine 29: 7251-7260. 
17. Butrapet et al. (2006) Determining genetic stabilities of chimeric dengue vaccine 
candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA. 
Journal of Virological Methods 131: 1-9 
18. Brault AC et al. (2011) Replication of the Primary Dog Kidney-53 Dengue 2 Virus 
Vaccine Candidate in Aedes aegypti is Modulated by a Mutation in the 5’ Untranslated 
Region and Amino Acid Substitutions in Nonstructural Proteins 1 and 3. Vector-borne 
and Zoonotic Diseases 11: 1-7. 
19. Huang C Y-H et al. (2000) Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue 
Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine. Journal of Virology 
74: 3020-3028. 
20. Butrapet S et al. (2000) Attenuation Markers of a Candidate Dengue Type 2 Vaccine 
Virus, Strain 16681 (PDK-53) are Defined by Mutations in the 5’ Noncoding Region and 
Nonstructural Proteins 1 and 3. Journal of Virology 74: 3011-3019. 
21. Huang C Y-H et al. (2003) Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent 
Dengue Vaccine Development. Journal of Virology 77: 11436-11447. 
22. Kinney RM et al. (1997) Construction of Infectious cDNA Clones for Dengue 2 Virus: 
Strain 16681 and Its Attenuated Vaccine Derivative, Strain PDK-53. Journal of Virology 
230: 300-308. 
23. Costa RL et al. (2012) Comparative evolutionary epidemiology of dengue virus 
serotypes. Infection, Genetics, and Evolution 12: 309-314. 
24. Pereira de Souza R et al. (2011) Dengue Virus Type 4 Phylogenetics in Brazil 2011: 
Looking beyond the veil. PLoS Neglected Tropical Diseases 5: e1439 
25. Lanciotti RS et al. (1997) Molecular evolution and phylogeny of dengue-4 viruses. 
General Virology 78: 2279-2286. 
26. Fried JR et al. Serotype-Specific Differences in the Risk of Dengue Hemorrhagic Fever: 
An Analysis of Data Collected in Bangkok, Thailand from 1994 to 2006. PLoS Neglected 
Tropical Diseases 4: e617. 
27. Mota J et al. (2002) Phylogenetic analysis of the envelope protein (domain III) of dengue 
4 viruses. Salud Publica de Mexico 44: 228-236. 
28. Foster JE et al. (2003) Molecular evolution and phylogeny of dengue type 4 virus in the 
Caribbean. Journal of Virology 306: 126-134. 
89 
!
29. Rossi SL et al. (2012) Genetic and phenotypic characterization of sylvatic dengue virus 
type 4 strains. Journal of Virology 423: 58-67. 
30. Knipe, D. M. & Howley, P. M. (2007). Field’s Virology (5th ed.). Philadelphia, PN: 
Lippincott-Raven Publishers. 
31. Sanchez-Vargas I et al. (2009). Dengue Virus Type 2 Infections of Aedes aegypti Are 
Modulated by the Mosquito’s RNA Interference Pathway. PLoS Pathogens 5(2): 
e1000299. 
32. Diaz-Nieto LM et al. (2013) Geographical Limits of the South Eastern Distribution of 
Aedes aegypti (Diptera, Culicidae) in Argentina. PLoS Neglected Tropical Diseases 7(1): 
e1963. 
33. Flipse J et al. (2012) Molecular Mechanisms Involved in Antibody-Dependent 
Enhancement of Dengue Virus Infection in Humans. Traffic: 1-11 
34. Hughes HR et al. (2012) Manipulation of immunodominant dengue virus E protein 
epitopes reduces potential antibody-dependent enhancement. Virology Journal 9:115 
35. Chan KR et al. (2011) Ligation of Fc gamma receptor IIB inhibits antibody-dependent 
enhancement of dengue virus infection. PNAS 108(30): 12479-12484 
36. Jessie K et al. (2004) Localization of Dengue Virus in Naturally Infected Human Tissues, 
by Immunohistochemistry and In Situ Hybridization. Journal of Infectious Diseases 189: 
1411-1418 
37. Rajapakse S et al. (2012) Treatment of dengue fever. Infection and Drug Resistance 5: 
103-112 
38. Wahala MP et al. (2011) The Human Antibody Response to Dengue Virus Infection. 
Viruses 3: 2374-2395 
39. Schmidt AG et al. (2010) Peptide Inhibitors of Dengue-Virus Entry Target a Late-Stage 
Fusion Intermediate. PLoS Pathogens 6(4): e1000851 
40. Huang CY-H et al. (2009) The dengue virus type 2 envelope protein fusion peptide is 
essential for membrane fusion. Journal of Virology 396: 305-315 
41. Byrd CM et al. (2013) A Novel Inhibitor of Dengue Virus Replication That Targets the 
Capsid Protein. Antimicrobial Agents and Chemotherapy 57(1): 15-25 
42. Watanabe S et al. (2012) The Magnitude of Dengue Virus NS1 Protein Secretion Is 
Strain Dependent and Does Not Correlate with Severe Pathologies in the Mouse Infection 
Model. Journal of Virology 86(10): 5508-5514 
43. Le Breton M et al. (2011) Flavivirus NS3 and NS5 proteins interaction network: a high-
throughput yeast two-hybrid screen. BMC Microbiology 11: 234 
90 
!
44. Cleaves GR et al. (1981) Identification and Characterization of Type 2 Dengue Virus 
Replicative Intermediate and Replicative Form RNAs. Journal of Virology 111: 73-83 
45. Tsai W-Y et al. (2012) C-Terminal Helical Domains of Dengue Virus Type 4 E Protein 
Affect the Expression/Stability of prM Protein and Conformation of prM and E Proteins. 
PLoS One 7(12): e52600 
46. Korrapati AB et al. (2012) Adenovirus Delivered Short Hairpin RNA Targeting a 
Conserved Site in the 5’ Non-Translated Region Inhibits All Four Serotypes of Dengue 
Viruses. PLoS Neglected Tropical Diseases 6(7): e1735 
47. Smith KM et al. (2012) Testing of Novel Dengue Virus 2 Vaccines in African Green 
Monkeys: Safety, Immunogenicity, and Efficacy. American Journal of Tropical Medicine 
and Hygiene 87(4): 743-753 
48. Sabchareon A et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD 
tetravalent dengue vaccine in Thai schoolchildren: a randomized, controlled phase 2b 
trial. Lancet 380: 1559-1567 
49. D’Arcy A et al. (2006) Purification and crystallization of dengue and West Nile virus 
NS2B-NS3 complexes. Structural Biology and Crystallization Communications 62:157-
162 
50. Falgout B et al. (1989) Proper Processing of Dengue Virus Nonstructural Glycoprotein 
NS1 requires the N-Terminal Hydrophobic Signal Sequence and the Downstream 
Nonstructural Protein NS2a. Journal of Virology 63(5): 1852-1860 
51. Lundin M et al. (2003) Topology of Membrane Associated Hepatitis C Virus Protein 
NS4B. Journal of Virology 77(9): 5428-5438 
52. Mackenzie JM et al. (1998) Subcellular Localization and Some Biochemical Properties of 
the Flavivirus Kunjin Nonstructural Proteins NS2A and NS4A Journal of Virology 245: 
203-215 
53. Hidari K et al. (2011) Dengue virus receptor. Tropical Medicine and Health 39(4): 37-43 
54. Bhamarapravati N et al. (1987) Immunization with a live attenuated dengue-2-virus 
candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in 
adult volunteers. Bulletin of the World Health Organization 65(2): 189-195 
55. Mulhern K (2010) DENVax Live Attenuated Chimeric Dengue Vaccine. Master’s Thesis, 
Colorado State University 
56. Sun W et al. (2003) Vaccination of Human Volunteers with Monovalent and Tetravalent 
Live-Attenuated Dengue Vaccine Candidates. American Journal of Tropical Medicine 
and Hygiene 69(Suppl 6): 24-31 
91 
!
57. Blaney JE et al. (2010) Targeted Mutagenesis as a Rational Approach to Dengue Virus 
Vaccine Development. Current Topics in Microbiology and Immunology 338: 145-158 
58. Johnson AJ et al. (1998) New Mouse Model for Dengue Virus Vaccine Testing. Journal 
of Virology 73(1): 783-786 
 
